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ABSTRACT
Superovulation is an assisted reproductive technique used to hyperstimulate the
ovaries in an attempt to proliferate desirable genetics by increasing the number of
dominant follicles and oocytes available per estrous cycle. Unfortunately, the process is
inefficient and costly due to FSH injection protocols, labor requirements, and animal
stress. A sustained release implant as a novel FSH delivery mechanism could increase the
efficiency and utility while reducing cost and animal stress. The objectives of these
experiments were: to design and fabricate a sustained FSH release implant and evaluate
the amount of FSH released in-vitro and in-vivo.
Polyethylene glycol diacrylate (PEGDA) was examined in six in-vitro
experiments to determine its usefulness as the base material for a sustained FSH release
implant. Overall, PEGDA released a maximum of 36 % of the total protein over 24 h
perhaps because the majority of the protein remained bound to the implant, suggesting
the protein may have been trapped in the cross-linked matrix during polymerization. A
second substance (polyacrylamide) was also examined for efficacy as an implant
material, in six in-vitro experiments. A 15 % acrylamide implant containing 2.5 mg pFSH
with an outer-scaffolding of a 0.6 ml Eppendorf™ tube (0.5 ml total volume), released 84
% of the total protein over 24 h.
Two in-vivo trials were performed using two different types of polyacrylamide
implants. In the first trial, gelding horses were divided into three groups: control,
injection, and implant. Serum FSH concentrations were determined by
radioimmunoassay and results were analyzed by ANOVA. The injection group was found
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to have significantly lower FSH concentrations than both the control and implanted
groups. Wide variations (greater then 20 ng/ml) in gelding FSH concentrations apparently
masked any treatment effects. In the second trial, Holstein heifers were divided into two
groups: FSH injection and FSH implant. Serum FSH concentrations were determined by
radioimmunoassay and results were analyzed by repeated measures ANOVA. Follicular
development and ovulation numbers were determined by transrectal ultrasonography.
There were no significant differences (P= 0.4561) in serum FSH concentrations between
groups; however, there were large differences (P= 0.004; Mean ± SEM ovulations/heifer)
in the number of ovulations between the injection group (13.5 ± 2.77) and the implant
group (1.8 ± 0.20). Additionally, while development of the largest follicle for each heifer
remained similar (P > 0.05) between groups the second largest follicle for the implant
group was significantly smaller (P= 0.0024) when compared to the injection group. The
ovulation and follicular development data suggested that the implant’s FSH was unable to
stimulate the ovary, despite reaching systemic circulation. One possibility was that the
bioactivity of the implanted FSH was impaired.
In-vitro results reveal a consistent release of FSH from polyacrylamide implants;
however, further studies are required to determine the usefulness of this sustained FSH
release implant in-vivo. Evaluation of the bioactivity of the FSH released from an implant
and the effects of this FSH at the level of the ovary will be important to advance this area
of research. The preliminary data in this thesis provides a compelling foundation to
advance this work and focus on the development of an efficacious FSH implant to
facilitate superovulation.
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CHAPTER ONE
REVIEW OF LITERATURE
Introduction
Assisted reproductive technology (ART) encompasses a wide range of techniques
such as artificial insemination, superovulation, embryo transfer, and in-vitro fertilization,
in an attempt to proliferate desirable genetics. Superovulation is a growing field primarily
used in human reproduction and agriculture. The Centers for Disease Control and
Prevention reported that 127,977 human ART cycles had been performed in 2004, in the
411 reporting clinics (CDC, 2006). The International Embryo Transfer Society (IETS,
2005) reported 116,993 bovine embryo collections occurred worldwide in 2005. FSH
delivery is necessary for superovulation; however, the results are inefficient and costly.
Humans, cattle, and horses release FSH in a bi-modal (occasionally tri-modal) surge
pattern to stimulate waves of follicular growth. Superovulation attempts to amplify the
endogenous FSH surge with exogenous FSH (lasting four to five days). Problems include
costly, labor intensive techniques and a high level of stress to the subjects.
Superovulation requires the use of FSH delivered in the correct dose during a particular
phase of the menstrual (humans) or estrous (cattle and horses) cycle; however, additional
hormonal supplementation (PGF2, GnRH, progesterones) are often used to optimize
results, thereby increasing the cost. Furthermore the cost from the labor associated with
the daily handling of cattle, is substantial. The stress of being handled could also affect an
animal’s response to the superovulation protocol. Inefficiencies and expense detract from
the usefulness of superovulation. The development of recombinant FSH or a novel FSH
2delivery mechanism in which there is a constant source of FSH could greatly improve
efficiencies. Additionally, implant could be placed on Day 1 and removed on Day 4 or 5
lowering labor costs and animal stress. The objectives of this research were to design and
fabricate a subcutaneous sustained FSH release implant, as a novel delivery system to
improve superovulation, and evaluate it in-vitro and in-vivo.
Follicle Stimulating Hormone
Follicle stimulating hormone (FSH) is produced by the basophilic cells in the
anterior lobe (pars distalis or adenohypophysis) of the pituitary gland. It is a member of
the glycoprotein hormone family, a group of disulfide-rich heterodimers, composed of
non-covalently associated  and  subunits. The alpha subunit is conserved among
species (Figure 1.1) with 92 amino acids, and is identical when compared to the alpha
subunit of other glycoprotein hormones such as luteinizing hormone (LH), thyroid-
stimulating hormone (TSH), and human chorionic gondadotropin (Li and Ford, 1998).
The beta subunit is conserved greater then 90 % among the bovine, ovine, porcine and
equine species (Figure 1.2) and differs among glycoprotein hormones (Fan and
Hendricks, 2005, Fujiki et al., 1977). M.D. Li and J.J. Ford (1998) suggested conserved
amino acid residues may be involved in functions that are universal to all the subunits,
such as peptide folding, receptor binding, or formation of the heterodimer. Bovine FSH
has a molecular weight of about 33kDa; however, this weight is species dependent and
can range from 30kDa to 37kDa due to differences in amount of glycoslyation. The half-
life of FSH is thought to be five hours or less (Monniaux et al., 1983).
3bovine MDYYRKYAAV ILAILSLFLQ ILHSFPDGEF TMQGCPECKL KENKYFSKPD APIYQCMGCC
ovine MDYYRKYAAA ILAILSLFLQ ILHSFPDGEF TMQGCPECKL KENKYFSKPD APIYQCMGCC
porcine MDYYRKYAAV ILAILSVFLQ ILHSFPDGEF TMQGCPECKL KENKYFSKLG APIYQCMGCC
equine MDYYRKHAAV ILATLSVFLH ILHSFPDGEF TTQDCPECKL RENKYFFKLG VPIYQCKGCC
bovine FSRAYPTPAR SKKTMLVPKN ITSEATCCVA KAFTKATVMG NVRVENHTEC HCSTCYYHKS
ovine FSRAYPTPAR SKKTMLVPKN ITSEATCCVA KAFTKATVMG NVRVENHTEC HCSTCYYHKS
porcine FSRAYPTPAR SKKTMLVPKN ITSEATCCVA KAFTKATVMG NARVENHTEC HCSTCYYHKS
equine FSRAYPTPAR SRKTMLVPKN ITSESTCCVA KAFIRVTVMG NIKLENHTQC YCSTCYHHKI
Figure 1.1 Amino acid sequence of the alpha subunit for bovine, ovine,
porcine, and equine FSH with differences highlighted in red. Sequences obtained
from NCBI and aligned using ClustlW.
porcine MKSLQFCFLF CCWKAICCNS CELTNITITV EKEECNFCIS INTTWCAGYC YTRDLVYKDAP
equine MKSVQFCFLF CCWKAVCCNS CELTNITIAV EKEECGFCIS INTTWCAGYC YTRDLVYKDAP
bovine MKSVQFCFLF CCWRAICCRS CELTNITITV EKEECGFCIS INTTWCAGYC YTRDLVYRDP
ovine MKSVQFCFLF CCWRAICCRS CELTNITITV EKEECSFCIS INTTWCAGYC YTRDLVYKDAP
porcine ARPNIQKTCT FKELVYETVK VPGCAHHADS LYTYPVATEC HCGKCDSDST DCTVRGLGPS
equine ARPNIQKTCT FKELVYETVK VPGCAHHADS LYTYPVATAC HCGKCNSDST DCTVRGLGPS
bovine ARPNIQKTCT FKELVYETVK VPGCAHHADS LYTYPVATEC HCSKCDSDST DCTVRGLGPS
ovine ARPNIQKACT FKELVYETVK VPGCAHHADS LYTYPVATEC HCGKCDRDST DCTVRGLGPS
Figure 1.2 Amino acid sequence of the beta subunit for porcine, equine,
bovine, and ovine FSH with differences highlighted in red. Sequences obtained from
NCBI and aligned using ClustlW.
In males, FSH targets receptors on the Sertoli cells of the testis, stimulating
sperm production (Brackett, 2004). In females, FSH targets receptors on the granulosa
4cells of the ovary, stimulating growth and development of follicles (Nimrod et al., 1976).
FSH initiates these responses through a G-protein linked reaction, which begins with
FSH binding to its receptor, activating adenylyl cyclase and producing cAMP. cAMP
then initiates a signaling cascade of growth and development, stimulating the production
of androgen-binding protein, ultimately resulting in spermatogenesis, in males (Brackett,
2004) and the growth of follicles in females (Fan and Hendrickson, 2005).
FSH secretion is controlled by the hypothalamus and gonads. Gonadotropin-
releasing hormone (GnRH) is secreted from the hypothalamus and transported through
the hypophyseal portal system to the anterior lobe of the pituitary gland, where it
stimulates the release of FSH and LH. Additionally, FSH may be modulated positively by
activin which is produced by the Sertoli cells of the male and the granulosa cells of the
female (Eiler, 2004). The Sertoli cells and granulosa cells also produce estrogen and
inhibin which work in concert in a negatively feedback on the anterior pituitary gland,
inhibiting FSH release (Thompson, 2004).
Superovulation and Embryo Transfer
Superovulation is the process of hyperstimulating follicular development, using
reproductive hormones such as FSH, in order to obtain multiple dominant follicles,
ovulations, and ooctyes and is commonly performed on cows, heifers, and mares. It is
often paired with estrous synchronization and embryo transfer. These processes are used
to proliferate desirable genetics by distributing embryos from valuable donors to
recipients who carry the fetus to term. Superovulation is considered to be inefficient and
5costly due to variable results, elevated hormone prices, labor requirements, animal stress,
and safety issues.
Additional concerns are species dependant. In the equine ovary, the cortical zone
lies on the interior of the ovary and the medulla or vascular zone makes up the outer layer
(opposite to these structures in the bovine). The cortical zone only reaches the surface of
the ovary at the ovulation fossa, limiting ovuations to a specific location, and causing
additional complications during superovulation (Blachard et al., 2003).
There are two commonly accepted methods of superovulating cattle, although
there are many variations in dose. The first method uses an injection (IM) of 1800–3000
IU (usually 2000–2500 IU) of equine chorionic gonadotrophin (eCG), followed by a
luteolytic dose of Prostaglandin F2 (PGF2) IM two to three days later. A second PGF2
injection is often given 12–24 h after the first to assure luteolytic regression of the corpus
luteum (CL). The second method of superovulation requires eight to ten injections of
porcine FSH (pFSH) given subcutaneously or IM at 12 h intervals. Injections must be
given every 12 h over four to five days due to the short half-life of pFSH, thought to be
five hours or less. PGF2 is given 48–72 h after initiation of pFSH treatment concurrent
with the fifth, sixth, or seventh pFSH injection. A common pFSH regimen for cows is 6,
6, 4, 4, 2, 2, 2, and 2 mg (total dose of 28 mg) at 12 h intervals with PGF2 given
concurrent with the sixth or seventh pFSH injection. Approximately 20 percent more
pFSH should be given to cows weighing over 800 kg (Siedel and Siedel, 2006). The
physiological differences between dairy cows and beef cows, and between cows and
6heifers, require tailoring of the regimen (Siedel and Siedel, 2006). These differences must
be considered before determining an FSH injection protocol.
The timing of FSH injections relative to the follicular wave is important. Bovine
and equine estrous cycles have two (or three) FSH surges and associated follicular waves
(Figure 1.3). Follicular recruitment and growth are stimulated by the FSH surge which
peaks at emergence (last day that the future dominant follicle is 4 mm; Day 0 in Figure
1.3). At follicular deviation (beginning of the greatest differences in growth rates between
the two largest follicles; Figure 1.3), the dominant follicle shifts from FSH regulated
growth to an LH dependent growth. FSH concentrations continue to decline causing the
regression of the subordinate follicles. Introduction of exogenous FSH early in the wave
will stimulate the growth of many dominant follicles (Ginther et al., 1996).
Superovulation attempts to heighten and broaden the endogenous FSH surge thus
exogenous FSH must be given early in the endogenous FSH wave. A study done by
Adams et al. in 1994 found no differences in ovulation numbers when exogenous FSH
was given on the day of emergence of the first wave compared to exogenous FSH given
on the day of emergence of the second wave of the bovine estrous cycle; however, when
FSH was given 1 day after emergence (approx. Day 1) fewer ovulations were found.
Another study by Lindsell et al., in 1986 compared ovarian response to FSH injections on
Day 3, Day 6, Day 9, and Day 12 of the estrous cycle. Day 9 was found to have the
greatest number of ovulations with Day 3 exhibited the lowest number of ovulations.
These studies indicated that the timing of the FSH injection is important to ovarian
response and should be considered before beginning a superovulation procedure.
7Figure 1.3 Model of FSH waves relative to follicular growth.
There are numerous approaches to performing superovulation in horses. Studies
have used pFSH, inhibin vaccines, eCG, equine pituitary extract (EPE), and equine FSH
(eFSH; Squires and McCue, 2006). To date, the most successful method of
superovulating a mare involves the use of eFSH. The eFSH manufacturers suggest 12 mg
of eFSH be administered at 12 h intervals for three to four days, stopping treatment once
the largest follicle is 32-35 mm. In a study done by Colorado State University mares
superovulated by this procedure had an average of 4.2 ovulations and 1.9 embryos
recovered (Squires and McCue, 2006).
8Variation in results among superovulation procedures could be caused by the
disparity in purity of commercial FSH. It is obtained post-slaughter from swine pituitary
glands (pFSH) for use in bovine superovulation or equine pituitary glands (eFSH) for
equine superovulation and is variable in biological activity from lot to lot. Also,
commercial FSH is contaminated with differing amounts of LH. One study (Hill et al.,
1984) found superovulatory response to a variety of lot numbers from the same
commercial source was not significantly different with the exception of those cattle
hyperstimulated with a lot dated 1979. The researchers suggested that lot to lot variation
caused minimal differences in superovulation provided lots were dated 1980 or above. A
different study (Braileanu et al., 1998) found “variability in the immunoactivity and
bioactivity both between and within commercial FSH preparations.” suggesting that this
variability could cause unpredictable superovulatiory response. Additional variation
maybe related to human error or animal stress. Advancements in a recombinant FSH
could minimize the lot to lot variation and LH contamination of commercial FSH, while a
novel FSH delivery method could help to minimize animal stress, injection profile
varation, and human error.
Mode of Hormonal Transportation
Hormones are defined as chemical agents, synthesized and secreted by glands,
which circulate via the blood to another portion of the body in order to stimulate specific
tissues (Eiler, 2004). Hormones must be transported from origin to target to induce their
biological responses. Knowing the mode of transport allows analysis of hormone
9concentrations, and enables researchers to assess hormone profiles and other important
characteristics.
Systemic circulation
The first and most commonly known mode of hormone transport is systemic
circulation through the blood. Some examples of hormones transported through systemic
circulation include FSH, LH, estradiol, testosterone, progesterone (Rhodes et al., 1995),
and insulin (Hector, 1926). The chemical structures of hormones can be divided into two
categories: steroid hormones and peptide/protein hormones. Steroid hormones such as
estradiol, testosterone, and progesterone are derived from cholesterol while
peptide/protein hormones such as FSH, LH, and insulin are made up of amino acids.
Steroid hormones range in size from 250 Da to 300 Da and are lipophilic. Peptide/protein
hormones vary widely in size ranging from a single amino acid (Triodothyronine and
Thyroxine) to large kDa structures (Eiler, 2004). There are few species to species
differences in steroid hormones while the chemical structure of the peptide/protein
hormones is often quite different among species. These chemical differences contribute to
different transport and absorption dynamics between steroids and peptide/protein
hormones. For example, steroids can be administered orally while the peptide bonds of
peptide/protein hormones will likely be digested and inactivated by gastrointestinal
enzymes (Eiler, 2004). Additionally, the lipophilic nature of steroids allows them to cross
cell membranes easily, permitting steroids to be transported quickly. While both types of
hormones can be transported systemically their structural and chemical differences cause
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variation in response. Additionally there are hormone-like substances such as
prostaglandins that are not considered classical hormones since they are produced
throughout the body (Eiler, 2004). Prostaglandins are arachidonic acid metabolites with a
single five carbon ring structure with two long side chains. They are lipophilic and have
diffusion properties similar to steroids (Goth, 1976), and will be classified with hormones
for the purpose of this thesis.
There are also more specific localized circulatory systems, examples of these
portal blood systems, are the hypophyseal portal system, renal system, and hepatic portal
system. Portal systems contain a cluster of veins that start and end in the capillaries,
preventing the hormone dilution in systemic circulation. The hypophyseal portal system
connects the hypothalamus to the anterior lobe of the pituitary gland allowing the
transportation of GnRH and other GnRH analogs, such as GnRH-II and GnRH-III (Islami
et al., 2001), although GnRH-II is also produced in areas outside the hypothalamus such
as the kidney, bone marrow, and prostate (Islami et al., 2001).
Another localized system that prevents hormone dilution is counter-current
exchange. Bayard et al., (1975) reported the transfer of testosterone in the spermatic cord
between venous and arterial blood (testosterone is also transported by systemic
circulation as mentioned above). Counter-current exchange is also shown by utero-
ovarian communication. The ovarian artery and utero-ovarian vein are found intertwined
in cattle and humans, allowing for steroid exchange and the movement of PGF2 from the
uterus to the ovary (Einer-Jensen and Hunter, 2005). Einer-Jensen and Hunter (2005)
suggested that the concentration of hormones transferred is subject to size; smaller
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hormones such as steroids are transferred more often while larger substances are not
transferred at all. Reports indicate that substances up to 3 kDa can be transferred via
counter-current exchange (Einer-Jensen and Hunter, 2005). Many hormones use carrier
molecules to promote faster transportation; however, this increases size and minimizes
any counter-current exchange (Einer-Jensen and Hunter, 2005). Minimal research has
been performed testing the possibility of using this utero-ovarian communication to
deliver non-steroid hormones, most likely due to the larger size of many protein
hormones.
Lymphatic circulation
A secondary mode of hormone transportation is circulation through the lymph
system. Recent research indicates that some hormones may be absorbed and transported
by the lymph system as well as through systemic circulation. Pezerovic-Panijan R. et al.
found in 2001 that parathyroid hormone (PTH) may be transported by the lymph as well
as by blood in fetal and postnatal humans; however, hormones circulated via the lymph
system eventually enter into systemic blood circulation through the thoracic duct.
Exogenous Hormone Introduction
Knowledge of hormonal transport has improved the delivery of exogenous
hormones. Based on the previously mentioned transportation options many modes of
injecting and implanting hormones into the body have been developed. The most
common techniques use eventual systemic circulation as the basis for injection,
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implantation, ingestion, and absorption. In all cases the hormone or drug’s physical and
chemical characteristics determine the speed of diffusion and absorption. Other
considerations in the diffusion/absorption process which affect administration include
interactions with indigenous carbohydrates (such as glycosaminoglycans) and proteins,
interstitial hydration, susceptibility of drug to degradation, size, concentration, volume,
pH, viscosity, and lipophilicity (McLennan et al., 2005).
Injections
Injections involve the insertion of a needle into various anatomical locations for
the administration of a drug or hormone. The specific purpose of injections varies widely.
For example, vaccines are injected to induce a protective immunological response against
the delivered antigen (Mutation/Genetic Engineering Techniques, 1998), providing
effective response to the same or similar antigen, virus, or disease during a later
exposure; however, for most hormonal injections the opposite is required. An ideal
hormonal injection will not stimulate an immune response. Hormonal injections
involving systemic circulation are injected three ways; subcutaneous, imtramuscular, and
intravenous.
Subcutaneous injections are placed under the skin. The skin is made up of three
layers; the epidermis, dermis and fat layer. The outer layer or epidermis can be further
broken down into stratus corneum, keratinocytes or squamous cells, and the basal layer.
The upper layers of the epidermis have a high turn-over rate while protecting the deeper
layers from harmful substances. The dermis is the middle layer and contains blood
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vessels, lymph nodes, hair follicles and sweat glands. The final layer is the deepest skin
layer consisting of fat and collagen which absorbs shock (UMMC, 2005). When
subcutaneous injections are administered, a depot forms in the space between the dermis
and the subcutaneous fat layer (Medlicott et al., 2003). The hormone then diffuses into
the blood vessels of the dermis and eventually into systemic circulation. There are
variations in the thickness and functionality of each skin layer among species. For
example, Shorthorn a breed of Bos tauraus, differs significantly in the depth of their
dermis layer and in the relative thickness of that layer when compared to the Zebu, Bos
indicus (Dowling, 1955). These differences must be considered before subcutaneous
injections are administered.
Intramuscular injections are deeper and delivered into the skeletal muscle located
beneath the subcutaneous fat layer. Skeletal muscle is striated and under voluntary
control of the animal. The injection must pass several cell layers, similar to that of the
subcutaneous injection. The skin layers, epidermis, dermis and fat layer must first be
traversed. Underneath the fat layer is the epimysium, a connective tissue layer that
surrounds the entire muscle. Muscles can be sub-divided into muscle fiber bundles, which
are surrounded by the periomysium. Further division is into the muscle fiber or cell of the
muscle, which is surrounded by the endomysium (Bailey, 2004). Large blood vessels and
nerves are located between the periomyseium and the muscle fiber bundles. An extensive
capillary network exists in the endomysium providing a nutritive supply to the muscle
cells. The lymphatics are located with the large blood vessels between the periomyseium
and the muscle fiber bundles (Medlicott et al., 2003). Drugs of low molecular weight can
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enter into systemic blood flow fairly quickly when injected into the muscle as they are
always near capillary beds, compared to drugs that travel first through the lymph system
and must move through a few cells before entering into the lymph. For both subcutaneous
and IM injections, drugs can be either absorbed into the capillaries (and from there into
systemic circulation) or into the lymphatic system. FSH, GnRH, and PGF2 are examples
of reproductive hormones given IM.
Similar to concerns with counter-current exchange, size affects the location where
molecules are absorbed. Small molecules are preferentially absorbed by the blood
capillaries because of high rate of filtration and re-absorption of fluid and high
permeability across the vascular endothelium. Macromolecules (>3kDaa) have limited
permeability, due to the tight junctions between opposing endothelial cells and a
continuous basement membrane, and are absorbed into the lymphatics from the
interstitial space (Figure 1.4).
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Figure 1.4 Schematic of drug delivery system; subcutaneous or IM.
When absorbed into the lymphatic capillaries, the drug must diffuse through an
outer layer of endothelial cells with a discontinuous basement membrane. Opposing
endothelial cells loosely adhere and overlap forming intercellular junctions along the
surface of the capillary, which are thought to be from 15- 20 nm to several µm wide
(McLennan et al., 2005). The junctions open and close in relation to interstitial volume
and pressure, facilitating the absorption of macromolecules (Figure 1.5).
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(McLennan et al., 2005).
Figure 1.5 Closeda and openedb lymphatic capillary intercellular junctions.
Intravenous injections are delivered directly into circulation via injection into a
vein therefore eliminating the diffusion period and reducing the time before the hormone
begins to stimulate a reaction; however, this mode of administration also greatly
decreases half life (Medlicott et al., 2003). Intravenous drugs must be of correct
osmolarity to prevent the lysis of blood cells which would disrupt blood flow. Xylazine,
and other sedatives are commonly given intravenously so they will work quickly to
tranquilize the animal.
The half-life of the drug is affected by the type of injection used to introduce it
into circulation. Drugs that are administered intravenously have a shorter half-life then
the same drug would if introduced via a subcutaneous or IM route because the
intravenously introduced drug is immediately placed into circulation and will be filtered
through the liver and renal system (Eiler, 2004). Drugs that are placed subcutaneously or
IM must first diffuse into capillaries before being affected by liver and renal filtration.
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The effect of subcutaneous injection compared with IM injection on half-life is widely
debated; however, studies examining recombinant FSH have found no significant
differences in the time taken for FSH to reach circulation (Kaplan et al., 2000, Voortman
et al., 2000).
Ingestion
Hormones can also be introduced into systemic circulation via the digestive tract
in locations such as the oral cavity, stomach, small intestine, colon, and rectum. The
gastrointestinal tract absorption rate is based on many of the same factors important to
injections. For those molecules that must be passively diffused (which occurs in the skin
and muscle) molecular weight, charge, lipophilicity, and size are all important
parameters. When passively diffusing into the intestinal tract, the location of the hormone
during absorption is important. Areas dense with villi (brush border) have higher
absorptive potential due to the increased surface area. The villus structure has one layer
of epithelial cells before blood and lymph vessels are available. The location of the villi
varies from species to species and must be considered before using an orally administered
hormone. Passive diffusion is not the only method of absorption into the gastrointestinal
tract (Takano et al., 2006). Unlike the previously mentioned routes, the intestinal tract has
transporters that can carry particular substances across the intestinal lining. For example,
there are carrier-mediated systems that move small, water-soluble nutrients from the
intestine into the blood stream (Takano et al., 2006). Di-/tripeptide transporter, PepT1, is
a peptide transporter located in the brush border membrane that moves many short
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peptides across the membrane barrier (Takano et al., 2006). The desired location of
absorption should determine the method of drug encapsulation. Drugs absorbed further
down the digestive tract will take longer to initiate a response then the same drug
absorbed earlier. Oral contraceptives and hormone therapy are examples of
gastrointestinal introduction of steroid hormones and have been researched extensively in
humans (Yoo and Chi, 2006). In May of 2006, over twenty-two brands of human oral
hormone and contraceptive therapies, delivering estrogen, progesterone or a combination
of both, were commercially available (Yoo and Chi, 2006). The liver removes a high
percentage of the hormones absorbed by the gastrointestinal tract before the hormone can
reach its target tissue. To counter this problem, high doses of the drug must be given to
stimulate the proper affect; however, this may cause deleterious side effects such as liver
disease and renal failure (Yoo and Chi, 2006). Injections would remove this variable;
however, most humans prefer an oral dose as an alternative to the more invasive
subcutaneous or IM injection due to the commonly held dislike of skin penetration by a
needle.
Transdermal
Another method of introducing exogenous hormones into the body is transdermal
delivery. The stratum corneum (the outer layer of the epidermis) is extremely resistant to
hydrophilic compound penetration. For highly lipophilic compounds (such as steroids)
the dermis provides the more resistant barrier (Riviere and Papich, 2001). The kinetics of
the drug or hormone determine diffusion time. Estrogen absorption is a slow, passive
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diffusion through the lipid domains in the stratum corneum which is enhanced when
diffusing through the rest of the epidermis and dermis, into microcirculation in the skin.
Transdermal application by-passes first-pass metabolism (liver) and allows for a lower
dose of hormone to be administered when compared to oral delivery. There are several
transdermal delivery systems including gels such as EstroGel™, emulsions such as
Estrosorb™ (Yoo and Lee, 2006), and contraceptive patches such as Ortho Evra™/Evra™
available. The Ortho Evra™/Evra™ patch contains the progestin norelgestromin
(previously known as 17-deacetylnorgestimate) and the estrogen ethinyl estradiol (EE).
Both of these synthetic steroid hormones are transdermally absorbed prior to entering the
systemic circulation (Pierson et al., 2003). Transdermal absorption can differ depending
upon placement, from individual to individual, and among species. The diffusion
differences among locations are due to differences in skin thickness, hair follicle density,
and other structural differences such as sweat gland location and density (Riviere and
Papich, 2001).
Subcutaneous implants
Subcutaneous implants are also used to introduce exogenous hormones. The
subcutaneous implant must diffuse and absorb through the same barriers as the
subcutaneous injection, yet have the advantage of slow release over a period of time, thus
increasing the duration of the drug’s effect. The first subcutaneous bovine implants were
impractical, large and bulky (one weighing 30 g, with 3 g of progesterone). The large
size, elevated amounts of hormone, and the need for surgical removal caused a lack of
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popularity of primitive subcutaneous implants (Rathbone et al., 1998). Currently,
subcutaneous implants are commonly placed in the ear. SYNCRO-MATE-B™ and
SYNCRO-MATE-C™ (releasing norgestomet) have been available commercially in
Europe for use in synchronizing estrus (Rathbone et al., 1998). Ralgro™ (zeranol
releasing) is a subcutaneous ear implant extremely popular in the United States in cattle
to increase efficiency of feed utilization (Matschke et al., 2002). COMPUDOSE™,
Synovex™ (Europe), and Crestar™ (Mexico) are also commercially available for
subcutaneous (ear) steroid release. Other subcutaneous systems used for veterinary
purposes, able to deliver non-steroidal substances, include ALZET™ used to induce
ovulation in exotic cats and pony mares, and SABER™ used for inducing ovulation in
mares and sows (Rothen-Weinhold and Gurny, 2000).
Intrauterine implants
Intrauterine implants are placed into the lumen of the uterus, either in the body or
the horns, and the drug is slowly released from the implant. The mammalian (specifically
the human, cow, and mare) uterus is made up of three layers; the serosa or perimetrium,
myometrium or muscularis, and endometrium or mucosa-submucosa (Priedkalns, 1993).
The outermost layer, the serosa, is made up of loose connective tissue covered by the
peritoneal mesothelium. The serosa layer contains many lymph and blood vessels, as well
as three major arteries and veins (branches of the vaginal, and uterine arteries and veins)
(Priedkalns, 1993). The location of the ovarian artery differs between ruminants and
horses (Blanchard et al., 2003). In ruminants, the ovarian artery and ovarian vein are
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intertwined allowing the countercurrent movement of PGF2, so there is minimal PGF2
in the systemic blood during luteolysis (Einer-Jensen and Hunter, 2005). Horses on the
other hand have less intimately attached ovarian artery and vein compared to ruminants
which causes a less efficient countercurrent movement of PGF2 (Blanchard et al., 2003).
PGF2 in horses is transported systemically causing serum concentrations to spike on Day
13-16 in non-pregnant mares (Blanchard et al., 2003). The second layer or myometrium is
the major component of the uterine wall and has three sub-layers (Priedkalns, 1993). The
thick inner layer is largely circular smooth muscle cells and the outer layer is smooth
muscle cells positioned longitudinally. The central layer is thick with abundant blood and
lymph vessels which supply the endometrium. The third layer or endometrium is
traditionally divided into two zones; the functional zone and the basal zone (Priedkalns,
1993). The functional zone is a superficial layer that partially or fully degenerates during
estrus (cows and mares) or the menstrual cycle (humans), depending on species. The
stage of the cycle determines the structure and height of the functional zone’s cells and is
related to the secretion of ovarian hormones, such as progesterone and estrogen
(Priedkalns, 1993). Beneath the epithelial cells, the functional zone is made up of
extremely vascular loose connective tissue with many immunological cells such as
neutrophils, macrophages, mast cells and plasma cells present (Priedkalns, 1993). The
deepest layer of the functional zone is also known as the perimetrium and is comprised of
loose connective tissue less cellular then the superficial previous layer (Priedkalns, 1993).
Certain species, such as ruminants, contain large areas of intracellular fluid in the
functional layer. The basal layer is a thin, deep layer that persists regardless of cycle
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stage and is responsible for restoring the functional zone after it is lost. Growth of the
tubular glands found in both the functional and basal zones is stimulated by rising
estrogen concentrations and secretory activity occurs via progesterone stimulation
(Priedkalns, 1993). Any drugs absorbed into the uterus must diffuse through the epithelial
cells of the endometrium and into the middle layer of the functional zone to be absorbed
into lymph or blood circulation.
The first intrauterine device (IUD) was created in the 1920’s by Dr. Grafenberg
who fashioned a helicoidally wound silver filament as a birth control device for humans.
It prevented pregnancy but raised some medical questions (Thiery, 2000). IUD’s have
been widely used for postmenopausal women as a method to deliver progesterones and
estrogens directly into the utero-ovarian system. Minera™ is an IUD containing progestin
and used as a contraceptive in humans. Also available, although not in the United States,
is the FibroPlant-LNG, the T-LNG14, and T-LNG5 intrauterine devices (Wildemeersche
et al., 2003, Yoo and Lee, 2005). Minimal research has been performed on non-human
species involving intrauterine devices due to concerns with contamination and infection,
the differences in estrous cycles, and the problems associated with threading an IUD
through the cervix of a cow or mare.
There has been research performed in horses using a glass or ceramic marble in
the uterus, for the suppression of estrus. A glass ball of 35 mm placed into the uterus of
mares acts to mimic the movement of the embryonic vesicle (Silva and Ginther, 2006)
and suppress estrus. In horses, this movement signals the maternal recognition of
pregnancy and prevents luteolysis, thus preventing a return to estrus (Silva and Ginther,
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2006). Unfortunately, retention of the glass ball is inefficient (only 5 of the 12 mares
remained out of estrus); however, this approach is an inexpensive, easy to administer, and
reversible method to suppress estrus (McCue, 2003).
Intravaginal implants
Intravaginal implants are placed in the lumen of the vagina. The vaginal wall is
made up of three layers: tunica mucosa-submucosa, tunica muscularis and the serosa. The
tunica mucosa-submucosa contains stratified squamous epithelium which thickens during
estrus. Shape varies with species: the mare has polyhedral epithelial cells while the cow
has a surface layer of columnar cells. The submucosal section consists of loose or dense
connective tissue with lymphatic nodes in the caudal region. The tunica muscularis has
two layers of smooth muscles. The inner layer is circular and separated into bundles by
connective tissue. The outer is a thin longitudinal layer of smooth muscle. The serosa is
made up of loose connective tissue, nerves, and large blood vessels. When compared to
the uterus, the vagina is much thicker with more cell layers between the lumen and blood
or lymph vessels (Priedkalns, 1993).
Intravaginal administration of bovine reproductive hormones began in the early
1960s with the delivery of progestogens. The first commercial bovine intravaginal
implant system was the progesterone releasing intravaginal device (PRID) followed
closely by another progesterone containing device, the CIDR-B™ (Rathbone et al.,
1998). The CIDR-B™ consists of a silicone rubber skin shaped in a “T” formation.with a
nylon core containing 1.9 g of micronised progesterone. The wings of the “T” hold the
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implant in place by exerting pressure on the vaginal walls. Both are still available
(although the PRID is not available in the USA). Intravaginal sponges and an intravaginal
application system (IVAS) have also been tested in cattle. Rings were researched for use
in cattle, but were found to be inappropriate for the bovine anatomy (Rathbone et al.,
1998). In contrast to their lack of use in the bovine, rings are used frequently in humans
for contraceptive and hormone therapy purposes. Estring™ (Pfizer) and Femring™
(Warner Chilcott) are both commercially available human intravaginal rings that release
progesterone (Yoo and Lee, 2006). The vaginal creams and gels were initially developed
for human estrogen administration and have since expanded to other steroid hormones.
Synapause™ (estrogen releasing) and Prochieve™ (progesterone releasing) are
commercially available but due to human error, response is highly variable. Also
available is a human vaginal tablet; Vagifem™ (Novo Nordisk, Denmark). This tablet
releases estrogen into the vagina as a form of hormone therapy (Yoo and Lee, 2006).
The newest application of intravaginal devices was developed for cattle and is the
intelligent breeding device (IBD). The IBD is a commercially available implant that
releases estradiol, PGF2, and progesterone at different rates and specific times. The
manager is then able to closely regulate the cow’s estrous cycle from afar (Rathbone et
al., 1998, Rothen-Weinhold and Gurny, 2000). Only steroid hormones and PGF2 have
been used thus far because of their small size and ability to move through tissue layers
into systemic circulation. Very little research has been performed with protein hormones
in the intravaginal and intrauterine spaces.
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Miscellaneous
As technology and functional anatomical knowledge increase in scope, novel
introduction methods are being developed. Injections into the joints and organs are being
studied. Intranasal vaccines for immunity against streptococcus equi (Equine strangles)
and the flu (humans) have become commercially available (Rothen-Weinhold and Gurny,
2000). Advances in hormone administration will continue to grow and change as old
challenges and problems are conquered and new ones arise.
Implants
There are several problems with injected hormones. Injected hormones generally
have short half-lives caused by a quick removal from circulation. This results in poor
target tissue response forcing an increase in the dose to compensate for the percent
removed by the liver or renal system. This increase in dose is costly and can also
stimulate liver or kidney disease. For target tissues that require prolonged hormonal
exposure for effect, injections provide variable results. Additionally, the opportunity for
human error increases each time an injection occurs and provides a chance of infection,
and irritation (Medlicott et al., 2004). Controlled release implants have been marketed to
overcome some of these difficulties. There are numerous controlled release implants
currently on the market and in diverse forms. They can be divided into three categories:
liquid formulations, in-situ solid formation, and solid implants.
26
Liquid Implants
The liquid controlled release implants are usually solutions, such as aqueous
suspensions, gels, and oil emulsions. The added material can prolong absorption time by
reducing diffusion rates in the depot formed during administration, while protecting the
hormone, thus increasing the active period. Looney et al. (1981) used a 3.2 % protein
gelatin carrier vehicle to extend the half-life of FSH and found that daily injections of
FSH with the gelatin carrier stimulated a greater number of follicles to develop and
ovulate when compared to twice daily injections of FSH. An aqueous solution can also
minimize irritation. Foster et al. (1997), compared water, oil, and microsphere
formulations of growth hormone release factor (GHRF), noting that the aqueous
formulation caused fewer irritations. Oil suspensions have been used to increase half-life
by extending the time it takes for hormones to enter into the blood stream. In 1999,
Posilac™ (an oil suspension of zinc bovine growth hormone) grossed $225 million in
sales, due to its propensity to increase milk production. In companion animals,
Program™ is an aqueous suspension of Lufenuron, a drug that interrupts an essential part
of the flea reproductive cycle, thus protecting the animal from fleas for 6 months
(Matschke et al., 2002). Ultralente™ insulin used to treat diabetes mellitus in cats is a
crystalline Zn-insulin suspension (Medlicott et al., 2003). Once in the body the crystalline
suspension gradually dissolves releasing the insulin at a controlled rate, resulting in the
need for only one injection per day versus multiple injections normally needed to
stabilize internal insulin concentrations.
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In-Situ Implants
In-situ forming implants are a recent advancement. The implant solution is
injected as a liquid and then solidified once in the correct location via temperature
changes, hydration, pH, or chemical interaction such as polymerization with ultraviolet
light. The solution must be of low viscosity so it can be injected with minimal
discomfort. Additionally, the in-situ formulation must be sterile and biodegradable to
prevent infection and removal issues. Deslorelin is a synthetic LH releasing hormone
agonist (peptide) found to be therapeutic in the treatment of cystic ovarian disease in
humans. Problems existed due to the quick rate of degradation that occurred when
injected alone; however, when added to the Pluronic™ F127 gel (a liquid to gel
formulation implant) the rate of degradation in human muscle tissue was significantly
decreased, allowing for a sustained deslorelin delivery, broadening the LH surge (Wenzel
et al., 2002). This system is liquid at room temperature but becomes a reversible semi-
solid at 37ºC. The SABER™ system is based on Sucrose acetate isobutyrate (SAIB) and
releases for one month (Matschke et al., 2002) for control and synchronization of estrus
for mares and sows. The Atrigel™ system is based on polylactide-acid (PLA)/polylactic-
co-glycolic acid (PLGA) and is used for growth enhancement. Both have been patented
in the past 10 years and are examples of in-situ formation technologies (Matschke et al.,
2002).
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Solid Implants
The third type of controlled release implant is a solid. Ralgro™ (Zeranol) is a well
known solid, biodegradable implant used in cattle to increase efficiency of feed
utilization (Sharp and Dyer, 1971). Solid implants have release patterns from one week to
several years and can be made of many different substances including: silicones,
polymers, and rubber. Most of the intrauterine and intravaginal implants are solid because
they can be removed without surgery from the uterus and vagina. Controlled internal drug
release, CIDR™, for example, is a non-biodegradable progesterone composed of a solid
silicone mold over a nylon core. There are some problems with solid implants including
the placement and removal of the implant. Often the implant is surgically placed resulting
in increasing chances of infections due to disruption of tissue; however most solid
implants are easily implanted and are biodegradable, minimizing complications.
Hydrogel Implants
Hydrogels are 3-D, polymeric networks that take in fluids, often causing an
increase in implant volume. They are made up of polymers that have chemical or
physical cross-linking ability, and can be classified under the in-situ forming or solid
implants. Their particular ability to swell with biological fluid causes them to resemble
natural living tissue more then other synthetic biomaterial (Peppas et al., 2000).
Research in hydrogels has included its use as scaffolds for tissue engineering and
as a drug delivery mechanism. They can be made from a wide variety of substances such
as alginate (Kuo and Ma, 2001), high-methoxy pectins (Sungthongjeen et al., 1999),
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biodegradable poly (2-hydroxy-ethyl-L-glutamine), poly (ethylene glycol) diacrylate
(PEGDA), and polyacrylamide (Marchant et al., 2004). Hydrogel drug delivery sites have
included ocular, nasal, oral cavity, transdermal, stomach, small intestine, colon, rectum,
vagina, and subcutaneous sites (Peppas et al., 2000). Hydrogel delivery can be controlled
by diffusion, chemical interactions, or the swelling of the hydrogel. This implant system
is one of the more efficient drug delivery mechanisms available.
Kinetics of Diffusion and Absorption
For those hormones not administered intravenously, the location of deposition and
the characteristics of the drug determine the speed and duration of the drug’s effect. Most
hormones are peptides or proteins and have disulfide bridges, while only about 15% are
steroids made from cholesterol. The larger, more complex hormones (such as
polypeptides) tend to stimulate an immune response while smaller molecules (such as
steroids) do not. Peptides or hormones containing several peptide bonds (about 85% of
known hormones) will not remain active when given orally due to the peptidases and
other enzymes, and the pH in the gastrointestinal tract, and must be administered by
another mechanism (Eiler, 2004). Larger molecules will diffuse at a slower rate when to
smaller molecules, and they take longer to move into the capillary systems. Drug
characteristics such as polarity also affect absorption rate. Hydrophobic and hydrophilic
differences cause large variations in the length of time a drug takes to enter systemic
circulation (Medlicott et al., 2004). For example, subcutaneous injections will differ
among individuals with differing amounts of fat (hydrophobic compounds will be
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delayed). Steroids are likely to bind by hydrophobic interaction in fat deposits and tend to
linger in fat whereas peptides do not and enter into circulation at a faster rate (Medlicott
et al., 2004). The delay causes the steroids to have a more prolonged effect then peptides
because they are more slowly absorbed into the blood stream (Eiler, 2004). The half-life
or fixed rate of decay is a drug characteristic that significantly affects the drug’s ability to
perform and its duration of activity. To be useful, the drug must have a half-life longer
then the period of time taken to diffuse, absorb, and be transported to its receptor (Eiler,
2004). As mentioned above, molecular weight is important in absorption because it
determines the circulation mechanism. High molecular weight drugs will enter into the
lymphatic capillaries and eventually enter into systemic circulation via the thoracic duct.
Lower molecular weight drugs will be absorbed into the blood capillaries and be
delivered directly into systemic circulation (Medlicott et al., 2004). Due to the differences
in individual tissues and the complexity of calculating diffusion rates, some experimental
variation is expected.
Conclusion
The variability and cost of superovulation make it obvious that new technology
must be developed to enhance the process and produce consistent results. A removable or
biodegradable implant for controlled FSH delivery placed on the first injection day and
removed on the last, could greatly decrease the cost of superovulation by decreasing labor
and variability. Subcutaneous placement provides an ideal location for implants as an
injection gun could be developed requiring no surgery for implantation. Hydrogels have
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been shown as the most efficient, highly successful material of the implant classifications
and would therefore be best for drug delivery.
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CHAPTER TWO
PEGDA IMPLANT EXPERIMENTS IN-VITRO
Introduction
Poly-ethylene glycol diacrylates (PEGDA) is a white powdered substance
produced by the acrylation of poly-ethylene glycol (Appendix B). When mixed in
solution and placed under UV light, PEGDA forms a hydrogel cross-linked matrix
capable of releasing protein.
For the following experiments PEGDA was used as the base substance and its
ability to release protein was assessed. Variations in mold, protein concentration, implant
volume, and polymerization time were examined to determine optimum implant
characteristics.
Objective
The objective was to determine if PEGDA could be a suitable base substance for a
subcutaneous FSH release implant.
General Materials and Methods
Formulation of PEGDA
The PEGDA recipe was acquired from Dr. A. Metter’s lab in the Chemical
Engineering Department, Clemson University and was formulated by Dr. Metter’s lab or
by Dr. A. Bodine’s lab in the Animal and Veterinary Sciences Department, Clemson
University (Appendix B).
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Bradford Protein Assay
A variation of the BIO-RAD protein assay, was used to analyze in-vitro samples
for protein release. The procedure was based on the BIO-RAD protocol, modified and
validated by Dr. T. Scott, Animal and Veterinary Sciences Department at Clemson
University (Appendix C).
Sampling
Once prepared, all implants were incubated at 37º C (Napco™ Model 6100 CO2
incubator) at 100 % humidity without CO2. The 5 ml of PBS surrounding each implant
was removed at Time points 0, 1, 2, 3, 4, 8, 16, and 24 hours (h) and 5 ml of fresh PBS
was added. Protein concentration from the sampled PBS was determined using the
modified BIO-RAD protein assay.
Protein Concentration
Porcine FSH (pFSH) was measured in international units (IU) of activity with 50
IU per bottle. For each experiment using pFSH the concentration of protein placed in the
implants was recorded in mg of pFSH (based on a dry matter weight) placed into the
implant; however, this includes other proteins that may be present in the lyophilized
protein. The contaminating protein may have the ability to alter polymerizing potential of
the implants and must be considered. An implant containing 50 IU of pFSH (one bottle of
pFSH) contains 12.5 mg of pFSH.
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Ranking System
Ranking systems were used in Experiment 2 and 4 to determine the most efficient
mold. Rank was based on ease of implant removal from the mold and level of
polymerization (polymerization was rated as poor or no polymerization, medium
polymerization, or strong polymerization, indicating a lack of residual liquid) and
integrity of the implant. Molds were ranked on a descending scale with the best being a
one, having strong polymerization, easy implant removal from the mold, and a high level
of implant integrity (no damage had occurred). The second rank (2) had strong
polymerization, but implant removal from the mold was more difficult. A high level of
implant integrity was questionable. The third rank (3) had medium polymerization
(indicating a small amount of residual liquid), implant removal from the mold was more
difficult causing some damage to the implant. The fourth rank (4) had poor
polymerization (copious residual liquid); however the implant was easy to remove and
suffered no damage. The final rank (5) had poor polymerization, and was difficult to
remove without considerable.
Experiment 1 – The release profile of protein from a 1 ml implant, with 15 % PEGDA
polymerized in glass
A release profile for PEGDA was characterized to determine its suitability as a
base substance for a sustained FSH release implant. Protein concentrations of 25 mg/ml
(two bottles of pFSH) and 12.5 mg/ml (one bottle of pFSH) were used to determine
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PEGDA protein release profile. Glass tubing was a readily available, cylindrical, UV
transparent mold and was used for this experiment.
Materials and Methods
Table 2.1 Recipe of a 1 ml, 15 % PEGDA implant at various protein concentrations.
Substance added Volume
added Additional notes
PEGDA 0.150 g 15 % was chosen based onpreliminary evaluation
Photoinitator-
Irgacure 2959
(Cibasc)
250 µl Taken from a stock
solution of 0.8 %
pFSH/PBS solution 500 µl Stock = 50 mg/ml25 mg
Implant PBS 100 µl
pFSH/PBS solution 250 µl Stock= 50 mg/ml12.5 mg
Implant PBS 350 µl
0 mg
Implant PBS 600 µl No pFSH added
Each of the 25 mg (n= 3), 12.5 mg (n= 3), and 0 mg (n= 3) pFSH implant
solutions was made and placed into glass tubes. Implant mixtures were then placed under
ultraviolet light (Model CM-10 fluorescence analysis cabinet, Spectronics Corporation,
Westbury, NY) at 365 nm for two hours to polymerize. After polymerization occurred,
glass tubes were broken to remove each implant. Implants were placed into individual
wells of a six well, flat bottomed plate (Corning Incorporated, Corning, NY) and 5 ml
PBS was added to each well. PBS surrounding each implant was removed at Time-points
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0, 1, 2, 3, 4, 8, 16, and 24 h and 5 ml of fresh PBS was added. Protein concentration in
the PBS was examined for each group (25 mg, 12.5 mg, and 0 mg) and results analyzed
by repeated measures ANOVA.
Results and Discussion
The cumulative Mean ± SEM protein release profiles of the three different protein
to volume implants were compared (Figure 2.1). The 0 mg of pFSH implants (blanks)
released 0 mg protein over the 24 h tested. The 12.5 mg pFSH implants released 4.02 ±
0.59 mg protein over 24 h (32 % of total protein). The 25 mg pFSH implants released
9.47 ± 1.11 mg protein over 24 h (36 % of total protein) which was a significantly higher
(p< 0.0001) release then found from the 12.5 mg implant .
The PEGDA implants were found to be capable of holding and releasing protein
(Appendix A) as recently reported (Sun and Chu, 2006); however, problems occurred
when attempts were made to remove implants from the glass mold. Implants could not be
removed from the mold without breaking the glass which facilitated broken, shards of
glass imbedded into the implants and/or caused the implants to break. Therefore another
type of mold was required, and experiments comparing plastic, wax, and glass molds
were performed.
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Figure 2.1 Cumulative Mean ± SEM release of protein over 24 h from 1ml, 15 %
PEGDA implants containing 0 mg, 12.5 mg, or 25 mg pFSH. Group (G), time (T)
and group*time (G*T) interactions were significant.
Experiment 2 – 1 ml implants with 15 % PEGDA polymerized in various molds
Materials and Methods
Implants solutions were a total of 1 ml volume, 15% PEGDA containing no
protein and polymerized in eight different molds (n= 4/mold; Table 2.2). Suture and
meshes were used in attempts to facilitate implant removal from the various molds. Each
implant was placed under ultraviolet light (365 nm), until polymerized (Table 2.2). Mold
usability was then analyzed by ease of removal from mold, integrity of implant, and
polymerization time.
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Table 2.2 Polymerization time allowed for various molds, using 1 ml PEGDA 0 mg
pFSH (blank) implants.
Mold material Polymerization Comments
½ cc Semen Straw Sheath
(AGTECH INC., Manhattan
KS) w/ nylon suture thread
~ 16 hours Thread suture through sheath but notprotruding through end
Glass test tube with nylon
suture ~ 2 hours
Thread placed in middle of implant
solution during polymerization
process
Glass test tube with knotted
nylon suture (~ every cm) ~ 2 hours
Thread placed in middle of implant
solution during polymerization
process
Glass tube with nylon mesh,
implant polymerized around
large nylon mesh (.04 cm X
.04 cm)
~ 4 hours
White nylon mesh placed around
inner circumference of glass tube,
implant solution poured in and
allowed to polymerize
Glass tube with implant
polymerized around small
nylon mesh (.01 cm X .01
cm)
~ 4 hours
White nylon mesh placed around
inner circumference of glass tube,
implant solution poured in and
allowed to polymerize
1.2 mm glass slides (Baxter
Healthcare Corp., McGraw
Park IL) with 1.5 mm
spacers (BIO-RAD Mini-
Protean II cell, Hercules CA)
~ 1 hour
Implant solution was placed between
two slides and rolled to get cylindrical
shape
Wax molded with semen
straw sheaths ~ 4 hours
Implant solution placed in a wax
mold
Glycerin soap (Life of the
Party, North Brunswick, NJ)
molded with semen straw
sheaths
~ 2 hours Implant solution placed in a soap
mold
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Results and Discussion
Molds were ranked from 1 (best) – 5 (worst). The best mold was determined to be
the wax mold (Table 2.3), based on the ease of implant removal and strong
polymerization of the PEGDA. All of the glass tube molds tested had to be broken before
implants could be removed, thus being unsuitable due to the possibility of retained glass
shards and inconsistent or damaged implants. The addition of the small nylon mesh
increased the implant’s ability to withstand physical pressures which indicated that the
mesh would be a useful addition to the implant makeup. This experiment suggests wax
may be a viable mold and the protein release profile of an implant polymerized in a wax
mold should be examined.
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Table 2.3 Analysis of different molds used to shape 1 ml, 15 % PEGDA implants
during polymerization. Rank (1-5, 1=best) was based on ease of implant removal
from mold and the level of polymerization.
Mold material Observations Ranking1(best) – 5 (worst)
Semen Straw Sheath w/
nylon suture thread
• Poor polymerization
• Poor removal 5
Glass test tube with nylon
suture
• Strong polymerization
• Poor removal
• Suture removed easily
5
Glass test tube with
knotted nylon suture (~
every cm)
• Strong polymerization
• Poor removal
• Suture resisted
removal
5
Glass tube with large
nylon mesh
• Strong polymerization
• Poor removal
• Increased implant
integrity
2
Glass tube with small
nylon mesh
• Strong polymerization
• Poor removal
• Increased implant
integrity
2
Glass Slides with 1.5 mm
spacers
• Strong polymerization
• Poor integrity 3
Wax molded with semen
straw sheaths
• Strong polymerization
• Easy removal 1
Glycerin soap molded
with semen straw sheaths
• Poor polymerization,
Implant solution
absorbed
5
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Experiment 3 – 1 ml implants with 15 % PEGDA polymerized in two types of wax molds
Materials and Methods
Paraffin (Richard Allan Scientific, Kalamazoo, MI) molds and beeswax molds
were made by heating each substance until liquified. Semen straw sheaths were placed
into cooling wax lengthwise so that half the diameter was in wax and other half above the
wax. Semen straws were placed in liquid wax, a minimum of 1.27 cm deep. If multiple
implants were made in one vat of wax, sheaths were placed a minimum of 1.27 cm apart
to prevent breaking of mold when the sheaths were removed (Figure 2.2). Wax was
allowed to fully harden (~ 4 h) at room temperature, then sheaths were removed leaving a
hemi-cylindrical indentation.
Figure 2.2 Three dimensional diagram of wax mold, with ½ cc semen straw sheaths
(blue) shaping the mold.
One ml 15 % PEGDA implant solutions of 0 mg pFSH (blank) and 12.5 mg pFSH
were then placed into a Paraffin or Beeswax mold (n= 3 per group; Paraffin 0 mg pFSH,
Paraffin 12.5 mg pFSH, Beeswax 0 mg pFSH, and Beeswax 12.5 mg pFSH), and
polymerized under 365 nm UV light for five hours.
1.27 cm
1.27 cm
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After polymerization, implants were removed from the mold and one implant was
then placed into each well of a six well plate with 5 ml of PBS. PBS surrounding each
implant was removed at Time-points 0, 1, 2, 3, 4, 8, 16, 24 and 48 h and replaced with 5
ml of fresh PBS. Results were analyzed by repeated measures ANOVA.
Results and Discussion
Blank (0 mg pFSH) beeswax mold implants released a cumulative Mean ± SEM
of 0.02 ± 0.02 mg protein and 0 mg pFSH paraffin mold implants released a cumulative
Mean ± SEM of 0.13 ± 0.09 mg protein over 48 h. The 12.5 mg pFSH beeswax molded
implants released a cumulative Mean ± SEM of 0.76 ± 0.13 mg protein and the 12.5 mg
pFSH paraffin molded implants released a cumulative Mean ± SEM of 0.70 ± 0.06 mg
protein over 48 h. Despite having a significantly higher release compared to the controls
the protein implants (12.5 mg pFSH in a beeswax mold and 12.5 mg pFSH in a paraffin
mold) released only 6 % of the protein (Appendix A, and Figure 2.3 ) and was
determined to be an unacceptable release rate when compared to the 32 % release found
from the 12.5 mg pFSH implants polymerized in glass molds. The protein most likely
was absorbed into the wax or bound to the wax instead of being held in the polymerized
PEGDA. Further study into other molds was required.
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Figure 2.3 Cumulative Mean ± SEM release of protein over 48 h from 1 ml, 15 %
PEGDA implants containing 0 mg or 12.5 mg pFSH, polymerized in either beeswax
or paraffin molds. Group (G), Time (T) and Group*Time (G*T) interactions were
significant.
Experiment 4 1 ml implants with 15 % PEGDA polymerized in plastic molds
Materials and Methods
Implants were made as 1 ml, 15% PEGDA implants containing no protein
(blank). Each implant was placed into one of three molds (Table 2.4), then placed under
UV light (365 nm), until polymerized. Results were then analyzed by ease of implant
removal from mold, level of polymerization, and integrity of implant.
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Table 2.4 Plastic molds used to polymerize 1 ml, 15 % PEGDA 0 mg (blank) pFSH
implants.
Mold Material Polymerization time Comments
Needle cap (16-ga. Needle
Becton Dickinson &
Company, Franklin Lakes NJ)
~ 10 hours Cap of a 16-ga. needle
Transfer pipet (Fisher
Scientific, Pittsburgh PA) ~ 10 hours
Implant solution placed in
bulb of transfer pipette
1 ml syringe (ST™ Becton
Dickinson & Company,
Franklin Lakes NJ)
~ 10 hours
Plunger was removed and
end of syringe sealed with
Critoseal™
Results and Discussion
Molds were ranked 1 (best) – 5 (worst) based on polymerization, ease of implant
removal from the mold, and implant integrity (Table 2.5). The 1 ml syringe mold was far
superior to any other mold tested (Table 2.5). Strong polymerization was obtained,
providing the implants with considerable integrity. Implants could also be easily removed
using the syringe plunger. A protein release profile from 1 ml implants with 15 %
PEGDA polymerized in 1 ml syringes was required to determine if the syringe could
fully replace the glass tube.
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Table 2.5 Subjective observations of mold material and its effects on
polymerization and ease of implant removal from mold.
Mold Material Observations Ranking1(best) – 5 (worst)
Needle cap • Strong polymerization
• Poor removal 4
Transfer pipette • Poor polymerization
• Poor removal 5
1 ml syringe • Strong polymerization
• Easy removal 1
Experiment 5 1 ml implant with 15 % PEGDA polymerized in 1 ml syringe
Materials and Methods
One ml of 15 % PEGDA solution, containing 0 mg pFSH (Blank) and 12.5 mg
pFSH implant (n= 2/each) solutions were made and placed into individual 1 ml
polypropylene syringes (the tip of the syringe were removed leaving only the barrel as the
mold). The syringes were then placed under UV (365 nm) light for ~12 h to polymerize.
After polymerization, implants were removed from the mold and was placed into a small
mesh bag. One implant was then placed into each well of a six well plate with 5 ml of
PBS. PBS surrounding each implant was removed at Time-points 0, 1, 2, 3, 4, 8, 16, and
24 h and replaced with 5 ml of fresh PBS. Groups (0 mg and 12.5 mg) were compared
using repeated measures ANOVA.
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Results and Discussion
The 0 mg pFSH implants (blank) released 0 mg protein. The 12.5 mg pFSH
implants released a cumulative Mean ± SEM of 4.42 ± .31 mg protein or 35 % total
protein release, over 24 h (Appendix A, Figure 2.4) and this was comparable to the 32 %
total protein released by the 12.5 mg implants polymerized in the glass tubes (Figure 2.1).
Additionally, the implants were much easier to remove from the molds with no
opportunity to retain glass shards or be damaged by removal. Therefore, the syringe was
considered the optimal mold.
The total protein release (35 %) was lower then expected. Therefore location of
the remaining protein was assessed to determine if PEGDA would be the proper base
substance for a sustained FSH release implant.
Figure 2.4 Cumulative Mean ± SEM release of protein over 48 h from 1 ml, 15 %
PEGDA implants, containing 0 mg (blank) or 12.5 mg pFSH, polymerized in a 1 ml
polypropylene syringe. Group (G), Time (T) and Group*Time (G*T) interactions
were significant.
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Experiment 6 Protein location following in-vitro release
Materials and Methods
Four 12.5 mg BSA, 15 % PEGDA implants were made and polymerized in 1 ml
syringes under UV light for 12 h. Two of the implants (Implants A and B) were placed
into dialysis tubing with 10 ml 0.5 % TBE buffer and exposed to electrophoresis in 0.5 %
TBE buffer. Tubing was positioned perpendicular to the current (100 volts) and eluted for
four hours to stimulate the in-vitro release of implants. Samples of the TBE buffer inside
the dialysis tubing were then collected and tested with BIO-RAD protein assay to
determine amount of protein released during the elution process.
Two eluted implants (Implants A and B) and two non-eluted implants (Implants C
and D) were separately ground coarsely using a mortar and pestle. The ground implants
were then placed into individual centrifuge tubes with 5 ml PBS and incubated for four
hours to allow for protein release. Tubes were then centrifuged at 1500 RPMS for 10
minutes. Supernatant and liquid surrounding the pellet was removed and analyzed using
the BIO-RAD protein assay. BIO-RAD dye was also added to the pellet and a color
change was observed indicating some protein remained in the implant.
Results and Discussion
Implants A and B released a Mean ± SEM of 0.28 ± 0.00 mg of protein after four
hours of elution. After centrifugation a Mean ± SEM of 0.08 ± 0.05 mg of protein was
found in the supernatant of Implants A, B, C and D; however, minimal protein was
released into the centrifuged supernatant from those implants that were first eluted (A and
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B) which indicated that the protein was able to diffuse out of the implant under
electrophoresis stimuli. A Mean ± SEM of 1.48 ± 0.16 mg of protein (Table 2.6) was
found in the liquid around the pellet formed after centrifugation. Overall, an average of
1.7 mg protein (14 % of total protein) was released from the implants (Table 2.6), with no
increase in protein release found when implants were eluted for four hours.
Table 2.6 Protein release from 12.5 mg BSA, 15 % PEGDA implants after each step
of Experiment 6.
Elution
(mg)
Supernatant
(mg)
Liquid surrounding
pellet (mg)
Total released
(mg)
Implant A 0.28 0.01 1.22 1.52
Implant B 0.27 0.00 1.21 1.48
Implant C N/A 0.19 1.85 2.04
Implant D N/A 0.13 1.64 1.77
Average 0.28 0.08 1.48 1.70
SEM 0.00 0.05 0.16 0.13
The lack of protein release from ground implants (increasing surface area)
indicated that perhaps pore size was not the limiting factor in protein release from these
implants. The bright color change observed when dye was added to the implant fragments
indicated that protein may have been physically bound to the implant during
polymerization. An additional possibility was that the protein was binding to the syringe
mold during polymerization; however, no color change was observed when molds were
rinsed with dye, making this unlikely. Based on the color change that occurred when dye
was added to the implant fragments, the majority of the protein remained in the cross-
linked matrix.
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Conclusion
Variations in protein concentration and type of mold were studied. The
polypropylene syringe was found to be the superior mold because it allowed UV light to
polymerize the implant and provided the easiest implant removal from the mold. The
highest percentage of protein release from 1 ml, 12.5 mg pFSH implants, polymerized in
syringes, was 36 % of the total protein. An experiment to determine the location of
remaining protein found a majority of the protein still attached to the implant, despite a
drastic increase in surface area (by coarse grinding of implant). This suggested the lack of
release from the implants was due to the binding of protein into the PEGDA matrix. A
base material that bound protein in the matrix was thought to be a poor choice for an in-
vivo sustained FSH release implant and a second base material (polyacrylamide) was
studied.
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CHAPTER THREE
IN-VITRO EXPERIMENTS WITH POLYACRYLAMIDE IMPLANTS
Introduction
Polyacrylamide is a hydrogel cross-linked matrix that is commonly used in
electrophoretic gels. Polyacrylamide gels are often used to separate proteins, indicating
that pore size could be large enough to enable FSH diffusion. The International Journal of
Toxicology published an article in 2005 stating “Polyacrylamide was not carcinogenic in
several chronic animal studies.” and that polyacrylamide was a well tolerated compound.
Polyacrylamide gels have also been extensively studied for use in humans. Currently,
polyacrylamide is found in cosmetics, contact lenses and pharmaceutical production
(Mole, 2005). Additionally, it has been used as an injectable skin filler for the treatment
of lipoatrophy, and other medical conditions (Fernandez-Cossio and Castano-Orega
2006, Mole, 2005). This suggested a low chance of implant rejection when placed
subcutaneously in test animals, making it a viable option for an implant base material.
Polyacrylamide pore size is dependent upon two factors: 1) the percent N, N1,
Methylene-bis-acrylamide (bis), and 2) the total percent of acrylamide. A 5 % bis
concentration will give the smallest pore size of any total concentration of acrylamide.
Pore size will also decrease as total concentration of acrylamide increases (5 % bis, 30 %
total acrylamide will have a smaller pore size than a 5 % bis, 10 % acrylamide). Another
polyacrylamide characteristic is the increasing rigidity of the gel as the total acrylamide
concentration increases. Higher percentages of acrylamide such as 40 % will be firmer
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than lower percentages of acrylamide such as 20 % (Menter, 2007). For the following
experiments a 5 % bis concentration was used in all acrylamide solutions. Variations in
volume, protein concentration, molds, total acrylamide concentrations, and scaffolding
were tested to obtain optimum implant assembly.
Objective
The objective was to determine if polyacrylamide could be a suitable base
substance for a subcutaneous FSH release implant.
General Materials and Methods
Bradford Protein Assay
A variation of the BIO-RAD protein assay was used to analyze samples of
distilled water that surrounded implants during incubation, for protein release. The
procedure was based on the BIO-RAD protocol, modified and validated in Dr. T. Scott’s
lab, Animal and Veterinary Sciences Department at Clemson University. For more
detailed information on this assay see Appendix C.
Sampling
Once prepared all implants were incubated in a 37º C incubator (Napco™ Model
6100 CO2 incubator) at 100 % humidity without CO2. The dH2O surrounding each
implant was removed at Time points 0, 1, 2, 3, 4, 8, 16, and 24 h and replaced with fresh
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dH2O. The dH2O removed at each time point was then tested for it protein concentration
using the modified BIO-RAD protein assay.
Protein Concentration
Similar to all PEGDA experiments, all polyacrylamide porcine FSH (pFSH)
experiments reported protein concentration in milligrams of protein placed into implant
and released for the following experiments, not in international units (IU). One bottle of
pFSH contained 12.5 mg of lyophilized protein and 50 IU of pFSH according to
manufacturer (Sioux Biochemical, Sioux Center, IA). One bottle of equine FSH (eFSH)
contained 25 mg of lyophilized protein and 100 IU of eFSH according to the
manufacturer (Bioniche Animal Health, Atlanta, GA).
Experiment 1 – Assessment of varying concentrations of total acrylamide
Materials and Methods
One ml solutions of 10 %, 15 %, 20 %, 30 %, and 35 % total acrylamide
concentrations (n= 4/concentration of acrylamide) were ranked on a scale of 1 (best) to 5
(worst) based on ease of implant removal from mold and level of integrity of the implant
(malleable, firm, or brittle, with firm being the best).
Final acrylamide solution was produced by combining stock acrylamide solution
(40%) and distilled water (Appendix D) which were brought to room temperature, mixed,
and placed under vacuum for 10 minutes. TEMED and an 10% w/v Ammonium
Persulfate solution were added (Appendix D), swirled, and loaded into a 1 ml syringe to a
53
final volume of 1 ml. The implant solution was allowed to polymerize within the syringe
for one hour. This procedure was repeated for each total concentration of acrylamide
(Appendix D). This experiment was performed to determine appropriate total acrylamide
concentrations based on ease of implant removal from mold and integrity of implant
structure, thus no protein was used. Rank was based on level of polymerization
(polymerization was rated as poor or no polymerization, medium polymerization, or
strong polymerization, indicating a lack of residual liquid) and integrity of implant.
Molds were ranked on a descending scale with the best being a 1. The top rank had strong
polymerization, and had a high level of implant integrity (maintained shape and was not
brittle). The second rank (2) had strong polymerization, with a high level of implant
integrity (although lower the rank 1). The third rank (3) had strong polymerization but is
more brittle then previously ranked implants. The fourth rank (4) had poor
polymerization (lots of residual liquid); however the implant maintains shape and was not
brittle. The final rank (5) had poor polymerization and did not maintain shape or was
extremely brittle.
Results and Discussion
The 10 % acrylamide concentration was found to be extremely malleable and had
a tendency to loose shape. The 30 % and 35 %, while firm, crumbled under pressure.
The 15 % and 20 % were firm enough to retain shape yet remained malleable enough to
yield under pressure and were determined to be the best potential implant concentrations
(Table 3.4).
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Table 3.1 Analysis of the integrity of polyacylamide implants at concentrations of 10
%, 15 %, 20 %, 30 %, and 35 % total acrylamide.
Total % PA Ranking1(best) -5(worst) Observations
10 % 4 Poor polymerization, malleable
15 % 1 Strong polymerization, flexible but firm
20 % 1 Strong polymerization, flexible yet resistant topressure
30 % 3 Strong polymerization, very firm, close to brittle
35 % 5 Strong polymerization, brittle
Experiment 2- Release profile of 1 ml PA implant with 20 % and 15 % total acrylamide
with 12.5 mg BSA
Materials and Methods
Bovine serum albumin (BSA; OmniPur™ EM Science, Gibbstown, NJ) was
substituted for FSH due to its larger size (~64 kDa), similar linear reaction to the BIO-
RAD protein assay, and reduced cost compared to pFSH.
Polyacrylamide implants were prepared at a concentration of 15% and 20% (n=
4/concentration of acrylamide) using a master mix for each respective trial. After the
addition of the polymerizing agents (TEMED and catalyst) four 1 ml aliquots were
produced. Three of the aliquots (for each polyacrylamide concentration) received 12.5
mg/ml treatment of BSA while the fourth served as a negative control (0 mg/ml BSA).
The aliquots were then loaded into 1ml polypropylene syringes. Implants were allowed to
polymerize for 1 hr, then removed from the syringes and placed into the wells of a six-
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well plate with 5 ml of dH2O. The dH2O surrounding each implant was removed at Time
points 0, 1, 2, 3, 4, 8, 16, 24, and 48 h and replaced with 5 ml fresh dH2O. Groups (15 %
acrylamide control, 15 % acrylamide containing protein, 20 % acrylamide control, 20 %
containing protein) were analyzed by repeated measures ANOVA.
Results and Discussion
Blank (0 mg) BSA implants for both 15 % and 20 % total acrylamide released 0
mg protein over 24 h. The 15 % implants released a cumulative Mean ± SEM of 9.34 ±
1.17 mg protein over 24 h or 74 % of total protein. The 20 % implants released a
cumulative Mean ± SEM 3.72 ± 0.26 mg protein over 24 h or 30 % of total protein
(Figure 3.1 and Appendix A) which was a significantly lower (p< 0.0001) amount of
protein then the 15 % implants.
The 15 % implants released a higher concentration of BSA over the 24 h tested
compared to the 20 % implant. The 20 % implant was thought to be the more viable
acrylamide concentration due to the increased structural integrity when compared to the
15 % implant. The 15 % implant would have been unable to remain intact when placed
under the pressures associated with subcutaneous implantation, and thus the 20 %
implant was chosen for further study. It also closely matched the release profile of the
PEGDA implants, without the problems associated with UV light polymerization.
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Figure 3.1 Cumulative Mean ± SEM release of protein over 24 h from 1 ml 15 %
and 20 % acrylamide implants containing 0 mg or 12.5 mg BSA, polymerized in a 1
ml polypropylene syringe. Group (G), Time (T) and Group*Time (G*T) interactions
were significant.
Experiment 3- Release profile of 2-ml PA implant with 20 % total acrylamide with 25 mg
equine FSH (eFSH).
Materials and Methods
For this experiment the 20 % total acrylamide implants were used to make 0 mg
eFSH (blanks; n=4) implants and 25-mg eFSH (Bioniche Animal Health, Athens GA)
implants (n=4; 2 ml volume and one bottle of 25 mg eFSH, per implant). Each implant
solution was then placed in a 3 ml polypropylene syringe (Becton Dickinson &
Company, Rutherford, NJ) and allowed to polymerize for two hours.
The implants were removed from the syringes and placed into individual 15 ml
sterile centrifuge tube (Fisher Scientific, Pittsburgh, PA) with 10 ml of dH2O. The dH2O
surrounding each implant was removed at time-points 0, 1, 2, 3, 4, 8, 16, 24, 48, and 72 h
and 10 ml fresh dH2O was added. Protein release from each group (blank and 25 mg) was
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analyzed using repeated measures ANOVA. Two 0 mg eFSH implants were placed in a
media-rich solution (10 % bovine calf serum in PBS, Hyclone, Logan, UT) and incubated
at 37º C without CO2 to evaluate contamination.
Results and Discussion
The 0 mg (blank) eFSH implants released 0 mg protein over 72 h. The 25 mg
eFSH implants released a cumulative Mean ± SEM of 14.63 ± 0.31 mg protein (59 % of
the total protein) over 72 h (Figure 3.2 and Appendix A). Release profiles were similar to
profiles found with pFSH; however, there was an additional 16 % total protein release
with the eFSH polyacrylamide implants in 24 h (46 % release from eFSH implants
compared to 30 % release from pFSH implants). This increase in protein release could be
due to the change in volume or due to differences in protein structure between the eFSH
and pFSH molecules. The 59 % total protein release was found to be satisfactory. The
implant was ready to try in a in-vivo (Chapter 4).
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Figure 3.2 Cumulative Mean ± SEM release of protein over 72 h from 2 ml, 20 %
acrylamide implants containing 0 mg or 25 mg eFSH, polymerized in a 3 ml
polypropylene syringe. Group (G), Time (T) and Group*Time (G*T) interactions
were significant.
The two 0 mg eFSH implants placed into the 10 % calf serum in PBS failed to
grow any observable bacteria or fungus, suggesting that contamination, if any, was
minimal and should not negatively affect test animals.
Experiment 4 - Release profile of 1 ml, 15 % PA implants with 12.5 mg BSA covered
with various polypropylene outer coverings.
Materials and Methods
An implant solution of 15 % total acrylamide was prepared. Directly after the
TEMED and catalyst solution were added, 1 ml of the solution was removed and placed
into each outer covering as 0 mg BSA implants (blanks). Then 12.5 mg BSA/ml solution
was added to either 1.9 ml polypropylene micro-centrifuge tube (Baxter Diagnostics Inc.
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Scientific Products, McGraw Park, IL), 3 ml polypropylene syringe, or 1 ml
polypropylene syringe in duplicate (yielding one blank and two BSA implants per test
covering material). Implants were allowed to polymerize for two hours.
Implants polymerized in the 3 ml syringe were then removed and placed into a
1.9 ml polypropylene micro-centrifuge tube. A 16-ga. needle (Becton Dickinson &
Company, Rutherford, NJ) was used to make holes through the 1.9 ml polypropylene
micro-centrifuge tube to facilitate protein release; three holes were punched down the
length of tube (1 cm space between holes), four around the circumference (totaling 12
holes), and one in the cap. The tip of the micro-centrifuge tube was also removed to
facilitate circulation and protein release (Figure 3.3). A 16-ga. needle was also used to
make four columns of holes through the 1 ml syringe at 0.1 ml intervals along the length
of the syringe. Implants were then placed into 15 ml sterile tubes with 10 ml dH2O. The
dH2O surrounding each implant was removed at time-points 0, 1, 2, 3, 4, 8, 16, 24, 48
and 72 h and replaced with fresh dH2O. 
 
Figure 3.3 Diagram of 1.9 ml micro-centrifuge tube, including placement of holes
(blue).
Cap- One hole
3 holes lengthwise, 4
around circumference
Tip cut off
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Results and Discussion
The 0 mg and 12.5 mg BSA implants polymerized in the 1.9 ml micro-centrifuged
tube released a cumulative Mean ± SEM 0.13 ± 0.13 mg protein and 6.24 ± 0.41 mg
protein, respectively. The 0 mg and 12.5 mg BSA implants polymerized in the 3 ml
syringe, with a 1.9 ml micro-centrifuge tube outer-scaffolding released 0.21 ± 0.21 mg
protein and 10.66 ± 0.08 mg protein, respectively. The 0 mg and 12.5 mg BSA implants
polymerized in 1 ml syringe, with a 1 ml syringe as outer-scaffolding released an average
of 0.34 ± 0.34 mg protein and 6.8 ± 1.01 mg protein, respectively. Therefore the 12.5 mg
BSA implants polymerized in the 3 ml syringe, with 1.9 ml micro-centrifuge tube outer-
scaffolding released the highest amount of protein (85 % total protein; Figure 3.4) and
was chosen for future research. This was perhaps due to the space between the implant
and the scaffolding, which provided more surface area and an avenue for circulation of
fluids, increasing the diffusion of BSA from the implant.
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Figure 3.4 Cumulative Mean ± SEM protein release over 72 h from 1 ml, 15 %
acrylamide implants containing 0 mg or 12.5 mg BSA polymerized in three different
molds. Group (G), Time (T) and Group*Time (G*T) interactions were significant.
Experiment 5- Release profile of 1 ml, 15 % PA implant with 6.5 mg pFSH covered with
1.9 ml polypropylene micro-centrifuge tube
Materials and Methods
One ml of the 15 % polyacrylamide formulation was placed into a 3 ml syringe
and allowed to polymerize for each of the four 0 mg implants (blanks). Four treatment
implants were made with one ml of the 15 % polyacrylamide formulation for each
implant and combined with 6.5 mg of pFSH per implant. Each implant solution (1 ml of
15 % formulation plus 6.5 mg pFSH) was then added to a 3 ml syringe and allowed to
polymerize for two h. After polymerization, each implant was removed and placed into a
1.9 ml polypropylene micro-centrifuge tube. The tip of each tube was removed and a 16-
ga. needle was used to place holes through the tube, three along the length of the tube and
four holes placed around the circumference, and a hole in the cap.
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The micro-centrifuge tubes were then placed into 15 ml sterile tubes with 10 ml of
dH2O. The dH2O surrounding each implant was removed at Time-points 0, 1, 2, 3, 4, 8,
16, 24, 48, and 72 h and replaced with fresh dH2O. 
 
Results and Discussion
A cumulative Mean ± SEM of 0.06 ± 0.02 mg protein was released from the
blank implants and 3.04 ± 0.30 mg protein was released from 6.25 mg implants. The 6.25
mg implants released 49 % of the total protein over 72 h (Figure 3.5); 10 % less than
obtained without the outer-scaffolding. This loss was acceptable because the outer-
scaffolding greatly increased the stability of the implant which would allow for ease of
in-vivo insertion and removal (see results and discussion section of Chapter 4). Concerns
about the size of the implant led to an experiment testing a decrease in dose, implant
volume, and scaffolding size. Additional changes in the placement and number of holes
placed in the scaffolding could increase the release of protein from the implant and
scaffolding, by increasing the surface area and circulation of fluids around the implant.
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Figure 3.5 Cumulative Mean ± SEM protein release over 72h from 0.5ml, 15 %
acrylamide implant containing 0 mg or 6.25 mg pFSH with 1.9 ml Eppendorf tube
outer- scaffolding. Group (G), Time (T) and Group*Time (G*T) interactions were
significant.
Experiment 6- pFSH release from a 0.5-ml, 15 % PA implant with 2.5 mg pFSH in 0.6-
ml Eppendorf tube scaffolding
Materials and Methods
A 15 % acrylamide implant solution was made (without TEMED). Two and a half
ml of this solution was then mixed with 5 µl of TEMED and 0.5 ml of the mixture was
placed into each 1 ml syringe (n= 5, 0 mg pFSH implants). Two and a half ml of the 15
% acrylamide implant solution was then added to one bottle of pFSH (12.5 mg) and
thoroughly mixed. 5 µl of TEMED was then added to the implant solution containing
pFSH and 0.5 ml of the mixture was placed into each 1 ml syringe (n= 5, 2.5 mg pFSH
implants). Implants were allowed to polymerize for three h then removed and placed into
0.6-ml Eppendorf tubes. Three columns of three holes were made in the Eppendorf tube
(by a 16-ga. needle), one in the cap, and the tip of the tube was removed. The micro-
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centrifuge tubes were then placed into 15-ml sterile tubes with 10 ml of dH2O. The dH2O
surrounding each implant was removed at time-points 0, 1, 2, 3, 4, 8, 16, 24, 48, and 72 h
and replaced with fresh dH2O. Repeated measures ANOVA was used to analyze the
groups (control and 2.5mg pFSH). Samples were also saved and frozen with 1% BSA to
evaluate pFSH protein release via radioimmunoassay (RIA).
Results and Discussion
Preliminary tests determined that polymerization would fail to occur at a
concentration of 15 mg/ml implant solution even though previous experiments had shown
that 12.5 mg/ml implant solution was possible. At a concentration of 5 mg/ml implant
solution the implants polymerized without problem.
A cumulative Mean ± SEM of 2.10 ± 0.16 mg was released from the 0.5 ml, 2.5
mg pFSH implants (Figure 3.5). This release was the greatest release of any of the
implants tested, releasing 84 % of the total protein in 24 h. The change in hole placement
in the outer-scaffolding and the decrease in volume, may have accelerated release. This
implant structure was used in the heifer trial (Chapter 4).
Samples analyzed by BIO-RAD protein assay and by RIA showed a relationship
(Figure 3.6) between concentration of total protein (BIO-RAD protein assay) and the
concentration of pFSH (RIA). This indicated that the BIO-RAD protein assay was a
reliable way of determining FSH release profile (Figure 3.7).
65
Figure 3.6 Cumulative Mean ± SEM release protein over 24 h from 0.5ml, 15
% acrylamide implants containing 0mg or 2.5 mg pFSH and a 0.6 ml Eppendorf
tube outer-scaffolding. Group (G), Time (T) and Group*Time (G*T) interactions
were significant.
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Figure 3.7 Graphical representation of the MEAN ± SEM in samples analyzed with
Bradford (total protein concentration) and RIA (FSH concentration).
Conclusion
Polyacrylamide was used as a base material with variations in acrylamide
concentrations, protein concentration, volume, and outer-scaffoldings to determine
optimum implant characteristics. Acrylamide concentrations of 15 % and 20 % provided
the most appropriate balance between structural integrity and sufficient pore size to allow
protein release. The 20 % total acrylamide concentration was initially chosen for further
experiments because it was considered more likely to remain structurally sound when
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placed subcutaneously. An outer-scaffolding provided greater structural integrity by
limiting the pressure placed on the base material which provided the opportunity to
decrease total acrylamide concentration from 20 % to 15 %, thus increasing pore size and
protein release. An Eppendorf tube provided the best outer-scaffolding of those tested
because of its shape, cap, and ability to contain the implant without interfering with
protein release. Protein concentrations of greater then 12.5 mg/ml were found to interfere
with polymerization; however, concentrations of 12.5 mg/ml or less had no difficulties.
Overall, the most beneficial implant characteristics were; an outer-scaffolding of a 0.6 ml
polypropylene Eppendorf tube, containing 0.5 ml volume, 15 % total acrylamide, with
2.5 mg of protein. When evaluated in-vitro, this implant released 84 % of the total protein
in 24 h, and was small enough to place under the skin of a heifer’s ear (Chapter 5).
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CHAPTER FOUR
IN-VIVO TRIAL WITH GELDINGS
Introduction
At the time of this trial gelded horses were available for use as test subjects. In
1987, Hoffman, Adams and Evans determined that gelding equine FSH (eFSH)
concentrations while significantly varying with time of year had no diurnal variation. In
2001, Collingsworth et al. determined that plasma gonadotrophin concentrations of
geldings were higher than concentrations in stallions. Plasma eFSH concentration varied
at most by 5 ng/ml among geldings. Additionally, the maximum plasma eFSH
concentration found in that study was approximately 17 ng/ml. Literature indicated little
problem with using geldings as a model so they were used to determine release of eFSH
from a subcutaneous implant.
Objective
The objectives of this experiment were to 1) determine if the 20% acrylamide
implant could withstand the pressures of implant insertion and removal, and 2) determine
if the concentration of FSH in the implant group would be higher than the concentrations
found in the control group, but similar to concentrations found in the FSH injected group.
Materials and Methods
Geldings were split into control, injected, and FSH implant groups (n= 4/per
group). Controls and injected had a 3 ml, 0 mg eFSH (blank), 20 % total acrylamide,
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implant placed subcutaneously beneath the fall of the mane. The FSH implant group had
a 3 ml, 20 % total acrylamide implant containing 25 mg (one bottle) of eFSH placed
subcutaneous beneath the fall of the mane.
Blood was drawn via jugular venipuncture at -24, -12, and 0 h relative to
implantation. At H 0 each animal was surgically prepped (clipped, area cleaned with
Nolvasan). A scalpel was used to make a small incision through the skin. Skin was pulled
away from muscle layer and the implant was inserted. In some cases forceps were used to
displace connective tissue between skin and muscle layers. Incisions were sutured with
monofilament. The injected group was given one eFSH injection (IM) after surgery (H 0)
and a second injection 12 h later (H 12). Each bottle of eFSH was reconstituted with 10
ml of sterile saline (5 ml, 12.5 mg eFSH equaled one dose).
After implant insertion, blood was drawn at 6 h intervals (6, 12, 18, 24, 30, 36, 42,
48 h) until 48 h, and at 12 h intervals (60, 72, 84 h) thereafter.
Implants were removed at H 48 by removing the suture and pushing the implant
out, all parts of the implant were recovered. Implant sites were thoroughly rinsed with
Nolvasan, and the incision was treated with triple antibiotic ointment. Geldings with
swelling or discharge at the site were lavaged at 12 h intervals until all swelling or
discharge had dissipated.
Blood was refrigerated for 12 h then allowed to come to room temperature. Tubes
were centrifuged at 2,100 RPMS for 20 minutes. If serum was not clear, tubes were spun
a second time at 2,100 RPMS for 20 minutes. Scintillation vials (7 ml, Fisher Scientific,
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Norcross GA) were filled with 5 ml of serum, and placed in a non-frost free freezer (- 20º
C) until equine radioimmunoassay (RIA).
RIA is the most common form of detecting FSH concentration in blood serum
(Hoffman et al., 1987, Collingsworth et al., 2001). The RIA procedure used to detect
eFSH concentration was based on suggestions provided by Dr. Parlow at UCLA Medical
Center’s (Torrence, CA) National Hormone and Peptide Program and modified by Dr. S.
Gray in the Endocrine Physiology Lab at Clemson University (Clemson, SC). Standards
for eFSH standards, first antibody, second antibody, and normal rabbit serum (NRS) were
all obtained from the National Hormone and Peptide Program (Torrence, Ca).
Serum samples were thawed and brought to room temperature.
Each sample and standard (0.78, 1.5, 3.1, 6.25, 12.5, 25, 50 ng/ml) was pipetted (100 µl),
in duplicate, into 12 X 75 mm borosilicate glass tubes. Radioiodinated eFSH, diluted to
approximately 15,000 counts per minute (CPM; efficiency was 80 %), was added to all
tubes (50 µl), including nonspecific binding (NSB), total counts (TC), and total bound
(TB). The first antibody (100 µl), NIDDK-anti-Hfsh-6 (rabbit) was added to all tubes
except NSB and TC. Tubes were vortexed, covered and incubated at room temperature
for 24 h.
After 24 h, the second antibody, goat anti-rabbit GG, was diluted to 1:300 in a 5
% PEG/PBS solution. Second antibody was added (1 ml) to all tubes except TC. A 1.5 %
solution of NRS in PBS was added (100 µl) to all tubes except TC. Tubes were incubated
at room temperature for four h. After four h tubes were centrifuged for 30 minutes at
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18,000 g. Tubes were then decanted (except TC) and placed in a Gamma Counter (4/600
Plus, ICN Biomedical, Huntsville, AL) and CPM determined.
All data were analyzed using repeated measures ANOVA.
Results
RIA data revealed a wide variation among horse’s eFSH concentrations (Figure
4.1). Significant group, time point, group, and time point by group interactions (P  0.05)
were found (Table 4.1). The injected group had significantly different eFSH
concentrations, at Time points -24, 0, 48, and 72, when compared to the control and FSH
implant groups. The longest rise in FSH levels occurred in the FSH implant group from
0-36 h (increase in FSH levels of approximately 11 ng/ml; Figure 4.2). The control had a
rise from 12-24 h (increase of ~ 5 ng/ml) as did the injection group (~ 4 ng/ml). eFSH
concentration among geldings within a group ranged from 8 ng/ml differences to greater
then 20 ng/ml differences (Table 4.1). Additional analysis with area under the curve
(AUC) found no significant differences (Appendix A) among groups.
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Figure 4.1 eFSH concentrations in geldings receiving 12.5 mg eFSH
injections (25 mg total), 25 mg eFSH implant, or blank implants (control; 0 mg
eFSH). Group (G), Time (T) and Group*Time (G*T) interactions were significant.
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Figure 4.2 eFSH concentrations in geldings during the 48 h treatment period
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Table 4.1 In-Vivo eFSH concentrations and range data for -24 to 72 h at 24 h time
intervals.
eFSH (ng/ml) Time Point (h) Control Injected FSH implant p-value
Conc. -24 15.7 ± 3.1 8.5 ± 1. 8 17.0 ± 5.3 P < 0.0001
Range 8.4 - 21.4 4.7 - 13.0 8.0 - 30.3
Conc. 0 14.2 ± 2.3 8.1 ± 2.0 10.3 ± 2.1 P = 0.0001
Range 8.9 - 20.1 3.8 - 12.2 5.9 - 14.4
Conc. 24 20.0 ± 1.8 16.1 ± 2.8 17.6 ± 4.9 P = 0.0664
Range 15.6 - 24.4 8.4 - 22.0 9.2 - 29.7
Conc. 48 17.0 ± 2.5 11 ± 1.9 16.5 ± 4.6 P = 0.0005
Range 12.0 -23.9 5.8 - 14.4 9.8 - 29.6
Conc. 72 18.9 ± 2.1 11.5 ± 2.1 18.1 ± 5.1 P < 0.0001
Range 15.4 - 24.0 9.3 - 35.8 9.9 - 32.8
AUC (H 0-72) ng/ml FSH/ trt hour 19.3 ± 1.8 17.6 ± 2.9 18.2 ± 5.5 p = 0.3786
Average range (H -24-72) 10.7 ± 1.0 14.6 ± 3.3 17.28 ± 4.1
Discussion
The implant was found to be insufficiently stable when put under the pressures of
insertion and removal. Most implants broke during the removal process making removal
of the implants difficult and indicating a outer-scaffolding maybe needed to prevent
fragmentation of the implants.
RIA levels indicated that wide variation among animals may have masked
treatment effects. For example, the injected group was found to be significantly lower in
eFSH concentrations compared to the control and the FSH implant, which confirmed that
individual horse variation may have altered results. Additional variation can be seen
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pretreatment. There was a significantly longer rise in the FSH implant group compared to
the control and injection groups. This steady rise in FSH suggested that the FSH from the
implant reached systemic circulation. Other factors (aside from variation caused by
animal-to animal differences) could have been due to the seasonal variation in
gonadotrophin secretion found in castrated geldings (Hoffman, 1987). This study was
performed in January, when horses are entering into the transitional phase of their
gonadotrophin secretion, which could explain the large horse-to-horse variation found
among the geldings in this experiment; however, even during the transitional phase long-
term castrated geldings have been reported to mimic stallion eFSH concentrations
(Hoffman, 1987). No literature was found to indicate a 10 ng/ml range is typical in
transitional phase stallions. Other factors such as low animal numbers and time from
castration could have contributed to the variation.
Conclusion
The large variation among horses may have masked any treatment effects and
could have been caused by the transitional phase of the gonadotrophin secretion cycle.
Implants did not remain structurally sound during the implantation and removal process,
which indicated the need for an outer-scaffolding. Further in-vitro studies are needed to
test the alteration in release profiles when an outer-scaffolding is used. Additional in-vivo
studies should examine FSH concentrations in geldings to determine if the wide amount
of variation seen in this experiment is typical.
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CHAPTER FIVE
IN-VIVO TRIAL WITH HEIFERS
Introduction
Superovulation protocols are commonly applied to valuable individuals within the
beef and dairy industries. Heifers were used for this study due to their heightened
response to exogenous hormones. Additionally, heifers are of particular interest because
they are a product of the more recent advancements in genetic research. Superovulation
and subsequent embryo collection of heifers facilitate an increase in genetic progress and
distribution of genetics within the cattle industry (Siedel and Siedel, 1991). The use of a
slow release FSH subcutaneous implant, to maximize FSH’s stimulating properties, has
the potential of improving the efficiency of these procedures and the yield of transferable
embryos per collection.
Implants were placed subcutaneously in the ear tissue because there are no
marketable meats in the ear. The ear provided an easily accessible surgery site when
animals were restrained by a head gate, without the susceptibility to trauma associated
with placement near the neck, shoulder, or flank of the animal. Additionally, other
subcutaneous implants have used been place in the ear (RalgroTM) with marked success
(Sharp, 1971).
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Objectives
The objective was to determine if FSH concentration, follicular diameter of the
two largest follicles and the number of ovulations would be similar between the FSH
injected group and the FSH implanted group.
Materials and Methods
Estrus was synchronized using a single injection (IM, 25 mg) of prostaglandin F2
(PGF2) and estrus was monitored for three days (standing estrus or red KAMAR). On
the fifth to seventh day after estrus (60 h prior to implantation, H -60) animals were bled
(~7 ml) via jugular venipuncture and twice daily for seven days starting 48 h prior to
implantation.
At H -48 ovarian status was assessed using transrectal ultrasonography. All
follicles greater then 6.5 mm were ablated in heifers with a corpus luteum (CL) using
transvaginal ultrasound guided follicular ablation approach. Heifers were randomly
allocated into injection (n=6) and FSH implant (n=5) groups. Twenty-four hours after
follicular ablation (H -24), all heifers were given 25 mg of PGF2 and received a CIDR
vaginal insert.
Transrectal ultrasonography was used to assess follicular response daily starting
48 h after follicular ablation (H 0). Implants were inserted subcutaneously in the left ear
through a small incision. The injected group received a 0 IU pFSH implant (blank) and
the implant group received an implant containing 10 IU of pFSH. In some cases forceps
were used to displace connective tissue between the skin and muscle layers. Incisions
were sutured closed. The injected group received pFSH injections (IM) every 12 h for
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four days starting at H 0. The injections were given in gradually decreasing doses (2.0,
1.5, 1.0, 1.0, 1.0, 0.5, 0.5, 0.5 ml) from 50 IU reconstituted with 20 ml sterile saline for a
total dose of 20 IU of FSH.
At H 48, the implants of the implant group were replaced with a new (10 IU
pFSH) implant. PGF2 (25 mg) was given at H 48 and CIDRs were removed 12 h later (H
60). Animals were monitored for signs of estrus and 2 ml of GnRH was given at standing
estrus or 48 h after CIDR removal (H 108). All implants were removed at H 96, and
animals with CL larger then 15 mm were given an additional dose of PGF2 (25 mg).
Transrectal ultrasonography was used to assess ovulation and CL numbers were recorded
seven days after GnRH injection.
Blood was refrigerated for 12 h then allowed to come to room temperature. Tubes
were centrifuged at ~12,000 g for 20 min. If serum was not clear, tubes were spun a
second time at ~12,000 g for 20 min. Scintillation vials (7 ml, Fisher Scientific, Norcross
GA) were filled with 5 ml of serum, and placed in a non-frost free freezer (- 20º C) to be
assayed by radioimmunoassay (RIA).
The RIA procedure used to detect FSH concentration was based on suggestions
provided by Dr. Parlow at UCLA Medical Center’s (Torrence, CA) National Hormone
and Peptide Program and modified by Dr. S. Gray in the Endocrine Physiology Lab at
Clemson University (Clemson, SC). Standard curve, first antibody, second antibody, and
normal rabbit serum (NRS) were all obtained from the National Hormone and Peptide
Program (Torrence, CA).
Serum samples were fully thawed and brought to room temperature.
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Each sample and standard (0.31, 0.62, 1.25, 2.0, 5.0, 10.0, 20.0 ng/ml) was pipetted (100
µl), in duplicate, into 12 X 75 mm glass tubes. The first antibody (anti-ovine FSH, lot #
AFPC5288113Rb) diluted 1:175 in PBSA, was placed (100 µl) in all tubes except non-
specific binding (NSB) and total counts (TC). The radioiodinated bFSH was diluted to
approximately 15,000 CPM and 50 µl was added to all tubes, including NSB, TC, and
total bound (TB). Tubes were shaken and then incubated at room temperature for 24 h.
After 24 h the second antibody, goat anti-rabbit GG (Rockland, lot # 16528), was
diluted to 1:300 in a 5 % PEG/PBS solution. This diluted second antibody (1 ml) was
added to all tubes except TC. A 1.5 % NRS in PBS (100 µl) was added to all tubes except
TC. Tubes were incubated at room temperature for four hours. After four hours tubes
were centrifuged for 30 minutes at 18,000 g. Supernatant was then decanted (except TC)
and placed in a Gamma Counter (4/600 Plus, ICN Biomedical, Huntsville, AL) and CPM
(floor efficiency was 80 %) determined.
Data from RIA were analyzed using repeated measures ANOVA.
Results
No significant differences were found between groups (P= 0.46) and there were
no significant group by time interactions (P= 0.0668); however, significant differences
were found over time (P < 0.0001). Despite no overall differences between groups
(Figure 5.1), differences were observed at H 12 (P= 0.02), H 96 (P= 0.02), and H 108 (P=
0.01). The Mean ± SEM follicle diameter of the two largest follicles (A and B) were
compared using repeated measures ANOVA. The diameter of the A follicle (largest
follicle) of the injection group was not significantly different over time (Figure 5.2) from
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the A follicle of the implant group (P= 0.1194); however, the diameter of the B follicle
(Figure 5.2) of the implant group was significantly different (P= <0.0001) when
compared to the B follicle of the injection group. Despite no overall differences the A
follicle of the injection group and implant group were significantly different at the Mean
maximum diameter (H 96; Table 5.1). Ovulation numbers were analyzed using single
factor ANOVA. The injection group had a significantly greater number of ovulations
when compared to the implant group (Table 5.1).
Figure 5.1 Mean ± SEM FSH concentrations in injected and implant groups relative
to implant insertion (H 0). Group (G), Time (T) and Group by Time (G*T)
interactions were analyzed.
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Figure 5.2 Mean ± SEM follicle diameter of follicles A and B comparing injection
and implant groups. Group (G), Time (T) and Group by Time (G*T) interactions
were analyzed.
Table 5.1 Mean ± SEM FSH concentrations every 24 h from 48 h prior to
implantation (H -48) to 120 h after implantation (H 120), Mean ± SEM diameter of
the two largest follicles (A and B) per group at H 96, and Mean total ovulations per
group.
Time (H) FSH Concentration (ng/ml)
Injected group Implant group p-value
-48 0.98 ± 0.07 0.80 ± 0.10 0.16
-24 1.07 ± 0.07 1.13 ± 0.13 0.47
0 1.22 ± 0.08 1.06 ± 0.05 0.21
24 0.95 ± 0.05 1.10 ± 0.23 0.24
48 0.87 ± 0.03 0.83 ± 0.09 0.76
72 0.80 ± 0.06 0.82 ± 0.12 0.83
96 1.02 ± 0.09 0.70 ± 0.18 0.02
120 0.71 ± 0.07 0.78 ± 0.08 0.57
Mean ± SEM maximum
diameter of A follicle 13.76 ± 0.81 12.21 ± 0.91 0.1194
Mean ± SEM maximum
diameter of B follicle 12.68 ± 0.55 9.78 ± 0.48 < 0.0001
Mean ± SEM Ovulations 13.5 ± 2.77 1.8 ± 0.2 0.004
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Discussion
Results indicated that FSH concentrations in the blood were similar between the
injection group and the implant group. Both groups showed an increase in systemic FSH
concentration after follicular ablation (H -48) typically associated with the emergence of
a new follicular wave (Berfelt, 1994). A significant difference between the injection
group and the implant group occurred at H 12. The injection group increased FSH
concentration in systemic circulation but the implant group decreased as the
concentrations of FSH found after follicular ablation declined. This increase in FSH
concentration at H 12 suggested that the injected FSH reached systemic circulation and
supplemented the FSH concentrations caused by follicular ablation within 12 h of
injection. The implant group’s FSH apparently did not reach systemic circulation by H 12
and thus showed a decrease as the FSH concentration from the follicular ablation
declined. The implant group did show an increase in FSH concentration at H 24
indicating that 24 h was perhaps needed for the implant’s FSH to reach circulation.
Minimal differences in time taken to reach systemic circulation were found when
subcutaneous injections of a recombinant FSH were compared to IM injections (le
Cotonnec et al., 1998), suggesting the delay in implant FSH entering systemic circulation
was due to the implant and not the subcutaneous placement of the implant. This is
comparable to the in-vitro research (Chapter 3, Experiment 6) which indicated 24 h may
be necessary for all protein to diffuse out of the implant.
Despite the encouraging RIA results, follicular mapping and ovulation data
indicated a poor response to FSH at the level of the ovary. The number of ovulations
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were very different between the injected and implanted heifers with all but one injected
heifer having greater then 10 ovulations compared with the implant group, wherein all
but one heifer had two ovulations. Additionally, when the largest two follicles were
compared, differences in growth rate over time were observed. The growth rates for the A
follicles in the injection and implant groups were similar overall; however, the growth
rate for the B follicles was significantly different when the injection group was compared
to the implant group. This indicated that the injected group had FSH concentrations
substantial enough to support the growth of many large follicles whereas the implant
group could only support the growth of one large follicle. This is further supported by the
higher numbers of ovulated follicles found in the injected group when compared to the
implant group. These results suggested that while the systemic FSH concentrations found
in the blood were similar, the implanted FSH was not able to stimulate follicular growth
beyond two dominant folllicles. This lack of follicular stimulation could be due to a
decreased receptor binding affinity, decreased half-life, a disassociation of the
heterodimers, or disruption of the glycolsylations. Damage to the O-linked
oligosaccharides of the FSH molecule could facilitate decreased half-life, receptor
binding, and bioactivity whereas damage to the N-linked oligosaccharides could affect
bioactivity (Fares F., 2006). Additionally, the cross-reactivity between the bovine RIA
and the exogenous pFSH introduced in this experiment was not known; however, data
comparing the samples of an in-vitro trial (Chapter 3, Experiment 6, Figure 3.6) using the
BIO-RAD protein assay and RIA to determine protein concentration indicated there was
some cross-reactivity.
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Conclusions
RIA results indicated FSH concentrations between the injection and implant
group were similar at all time-points except H 12, H 96, and H 108. Despite similar FSH
concentrations the injection group had a much higher number of ovulations compared to
the implant group. Follicular mapping showed a significant difference in follicle diameter
for the B (second largest) follicles of the implant group, which suggested the ovaries
lacked sufficient FSH to support further follicular growth. Overall results indicated FSH
was released from the implant but was not able to stimulate increased follicular growth.
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CHAPTER SIX
RECOMMENDATIONS
The 15 % acrylamide implant with 2.5 mg pFSH and an outer-scaffolding of a 0.6
ml Eppendorf tube provided a structurally sound subcutaneous implant that was capable
of releasing protein in-vitro over a 24 h period. When tested in-vivo with Holstein heifers,
this implant showed a FSH profile comparable to the FSH injection profile; however,
ovulation numbers suggested that the implant FSH was unable to stimulate follicular
development in the ovary. More research is required to determine if this implant could be
made suitable for use in a superovulation procedure.
Although the BIO-RAD protein assay and RIA measure the amount of protein and
FSH respectively, they do not test bioactivity. An experiment to determine the bioactivity
of FSH would establish if implant polymerization and/or protein diffusion damaged the
FSH molecule. Bioactivity could be determined by using the Steelman -Pohley rat
bioassay (Rose et al., 2000, Steelman and Pohley, 1953). If bioactivity were
compromised, further experimentation to determine the location of the damage would be
necessary. Specifically, an experiment to determine if the  and  subunit remain intact as
a heterodimer could be performed using a native polyacrylamide gel electrophoresis
(PAGE) where dissociation of the heterodimers would be evident by the appearance of
two bands instead of one. Additionally, experimentation to determine the damage to the
FSH glycosylations should be performed.
Further an in-vivo study with a greater number of animals would provide more
information on the consistency of FSH release from the implant, as well as provide
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information on the differences between an FSH implant and controls. Additional in-vivo
research could focus on determining the amount of implanted FSH reaching systemic
circulation. Radio-labeling exogenous FSH would allow for experimenters to determine
the differences between exogenous and endogenous FSH present in serum, thus providing
greater confidence in conclusions regarding implanted FSH release. Additional in-vivo
release could examine the timing of implant placement relative to endogenous FSH
surge.
Finally, the implant could be improved by changing the dimensions, the outer-
scaffolding, or even the base material. Polyacrylamide was better then the PEGDA;
however, it may not be the best possible base material for a sustained FSH release
implant. Other hydrogels should be tested and compared to results gained from the
polyacrylamide implants, allowing for the best sustained FSH release implant to be
produced.
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APPENDIX A
In-vitro and in-vivo raw data
Polyethylene-glycol diacrylate (PEGDA) implants
Experiment 1 – The release profile of protein from a 1 ml implant, with 15 % PEGDA
polymerized in glass
Table A.1 Cumulative release of protein (mg) over 24 h, from 1 ml, 15 % PEGDA
control implants (0 mg pFSH).
Implant Time (H)
0 1 2 3 4 8 16 24
# 1 0.31 0.00 0.00 0.00 0.00 0.00 0.00 0.00
# 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
# 3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
SEM 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Table A.2 Cumulative release of protein (mg) over 24 h, from 1 ml, 15 % PEGDA
implants containing 12.5 mg pFSH.
Implant Time (H)
0 1 2 3 4 8 16 24
# 1 0.04 0.79 1.11 1.27 1.71 2.90 4.03 4.83
# 2 0.05 0.59 0.84 0.95 1.03 1.11 2.24 2.88
# 3 0.00 0.86 1.29 1.49 1.59 2.50 3.64 4.34
Average 0.03 0.75 1.08 1.24 1.44 2.17 3.30 4.02
SEM 0.02 0.08 0.13 0.16 0.21 0.54 0.54 0.59
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Table A.3 Cumulative release of protein (mg) over 24 h, from 1 ml, 15 % PEGDA
implants containing 25 mg pFSH.
Implant Time (H)
0 1 2 3 4 8 16 24
# 1 0.18 1.89 2.85 4.08 4.67 7.16 9.28 10.73
# 2 0.32 2.29 3.53 4.27 5.18 7.42 9.59 10.41
# 3 0.21 0.21 1.17 2.18 3.24 5.08 5.08 7.27
Average 0.24 1.47 2.52 3.51 4.36 6.55 7.99 9.47
SEM 0.04 0.64 0.70 0.67 0.58 0.74 1.45 1.11
Experiment 3 – 1 ml implants with 15 % PEGDA polymerized in two types of wax molds
Table A.4 Cumulative release of protein (mg) over 48 h from 1 ml, 15 % PEGDA
control (0 mg pFSH) implants polymerized in a beeswax mold.
Implant Time (H)
0 1 2 3 4 8 16 24 48
# 1 0.00 0.00 0.04 0.07 0.07 0.07 0.07 0.07 0.07
# 2 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
# 3 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Average 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02 0.02
SEM 0.00 0.00 0.01 0.02 0.02 0.02 0.02 0.02 0.02
Table A.5 Cumulative release of protein (mg) over 48 h from 1 ml, 15 % PEGDA
control (0 mg pFSH) implants polymerized in a paraffin mold.
Implant Time (H)
0 1 2 3 4 8 16 24 48
# 1 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
# 2 0.00 0.00 0.00 0.07 0.07 0.07 0.07 0.07 0.07
# 3 0.00 0.00 0.10 0.25 0.25 0.25 0.25 0.29 0.31
Average 0.00 0.00 0.03 0.11 0.11 0.11 0.11 0.12 0.13
SEM 0.00 0.00 0.03 0.07 0.07 0.07 0.08 0.09 0.09
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Table A.6 Cumulative release of protein (mg) over 48 h from 1 ml, 15 % PEGDA
implants containing 12.5 mg pFSH, polymerized in a beeswax mold.
Implant Time (H)
0 1 2 3 4 8 16 24 48
# 1 0.21 0.32 0.37 0.50 0.50 0.50 0.50 0.53 0.53
# 2 0.19 0.31 0.36 0.48 0.48 0.48 0.48 0.75 0.75
# 3 0.17 0.37 0.47 0.57 0.57 0.57 0.57 0.98 0.98
Average 0.19 0.33 0.40 0.52 0.52 0.52 0.52 0.76 0.76
SEM 0.01 0.02 0.03 0.03 0.03 0.03 0.03 0.13 0.13
.
Table A.7 Cumulative release of protein (mg) over 48 h from 1 ml, 15 % PEGDA
implants containing 12.5 mg pFSH, polymerized in a paraffin mold.
Implant Time (H)
0 1 2 3 4 8 16 24 48
# 1 0.27 0.43 0.54 0.68 0.68 0.68 0.69 0.73 0.74
# 2 0.18 0.30 0.40 0.50 0.50 0.54 0.54 0.55 0.58
# 3 0.35 0.46 0.53 0.68 0.68 0.71 0.71 0.77 0.77
Average 0.27 0.40 0.49 0.62 0.62 0.65 0.65 0.68 0.70
SEM 0.05 0.05 0.05 0.06 0.06 0.05 0.05 0.07 0.06
Experiment 5 – 1 ml implant with 15 % PEGDA polymerized in 1 ml syringe
Table A.8 Cumulative release of protein (mg) over 48 h from 1 ml, 15 % PEGDA
implants containing 12.5 mg pFSH, polymerized in a 1 ml polypropylene syringe.
Implant Time (H)
0 1 2 3 4 8 16 24 48
# 1 1.34 2.33 2.70 2.99 2.99 3.31 3.79 4.14 4.73
# 2 0.85 1.58 2.07 2.30 2.30 2.67 3.07 3.44 4.11
Average 1.09 1.95 2.38 2.64 2.64 2.99 3.43 3.79 4.42
SEM 0.25 0.37 0.32 0.35 0.35 0.32 0.36 0.35 0.31
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Polyacrylamide Implants
Experiment 2- Release profile of 1 ml PA implant with 20 % and 15 % total acrylamide
with 12.5 mg BSA
Table A.9 Cumulative release of protein (mg) over 24 h from 1 ml, 15 % acrylamide
implants containing 12.5 mg BSA, polymerized in a 1ml polypropylene syringe.
Implant Time (H)
0 1 2 3 4 8 16 24
# 1 2.32 3.50 3.79 4.43 4.89 5.76 7.04 7.55
# 2 2.01 3.12 4.02 4.73 5.29 6.39 7.93 8.91
# 3 2.71 4.45 5.38 6.42 7.15 8.77 10.56 11.54
Average 2.35 3.69 4.40 5.19 5.78 6.97 8.51 9.34
SEM 0.20 0.40 0.50 0.62 0.70 0.92 1.06 1.17
Table A.10 Cumulative release of protein (mg) over 24 h from 1 ml, 20 %
acrylamide implants containing 12.5 mg BSA, polymerized in a 1 ml polypropylene
syringe.
Implant Time (H)
0 1 2 3 4 8 16 24
# 1 1.35 1.99 2.69 2.79 2.87 3.21 3.83 4.21
# 2 1.31 1.95 2.16 2.22 2.29 2.58 3.02 3.34
# 3 1.29 2.05 2.05 2.26 2.28 2.61 3.13 3.59
Average 1.31 2.00 2.30 2.42 2.48 2.80 3.33 3.72
SEM 0.02 0.03 0.20 0.18 0.19 0.21 0.25 0.26
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Experiment 3- Release profile of 2-ml PA implant with 20 % T acrylamide with 25 mg
equine FSH (eFSH)
Table A.11 Cumulative release of protein (mg) over 72 h from 2 ml, 20 %
acrylamide implants containing 25 mg eFSH, polymerized in a 3 ml polypropylene
syringe.
Implant Time (H)
0 1 2 3 4 8 16 24 48 72
# 1 3.27 5.82 6.35 6.77 7.30 8.84 10.97 12.54 14.37 15.42
# 2 3.45 4.76 5.35 5.75 6.26 7.73 9.70 11.28 13.06 14.08
# 3 3.28 4.42 4.97 5.55 6.01 7.48 9.61 11.16 13.07 14.15
# 4 3.60 5.10 5.51 5.92 6.44 8.07 10.16 11.79 13.68 14.86
Average 3.40 5.02 5.55 6.00 6.50 8.03 10.11 11.69 13.54 14.63
SEM 0.08 0.30 0.29 0.27 0.28 0.29 0.31 0.31 0.31 0.32
Experiment 4 - Release profile of 1 ml, 15 % PA implants with 12.5 mg BSA covered with
various polypropylene outer coverings
Table A.12 Cumulative protein release (mg) over 72 h from 1 ml, 15 % acrylamide
implants containing 12.5 mg BSA, polymerized in a 1.9 ml polypropylene micro-
centrifuge tube.
Implant Time (H)
0 1 2 3 4 8 16 24 48 72
# 1 1.58 2.81 3.17 3.39 3.60 3.96 4.36 5.09 5.81 6.65
# 2 1.93 2.76 3.13 3.23 3.33 3.52 4.17 4.65 5.26 5.84
Average 1.76 2.79 3.15 3.31 3.47 3.74 4.27 4.87 5.54 6.24
SEM 0.18 0.02 0.02 0.08 0.13 0.22 0.09 0.22 0.27 0.41
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Table A.13 Cumulative protein release (mg) over 72 h from 1 ml, 15 % acrylamide
implants containing 12.5 mg BSA, polymerized in a 3 ml polypropylene syringe then
covered with a 1.9 ml polypropylene micro-centrifuge tube.
Implant Time (H)
0 1 2 3 4 8 16 24 48 72
# 1 1.44 2.61 3.59 4.25 4.78 5.77 6.42 7.81 9.58 10.58
# 2 1.70 3.09 3.84 4.43 4.83 5.49 6.19 7.11 9.75 10.74
Average 1.57 2.85 3.71 4.34 4.81 5.63 6.30 7.46 9.66 10.66
SEM 0.13 0.24 0.12 0.09 0.02 0.14 0.11 0.35 0.09 0.08
Table A.14 Cumulative protein release (mg) over 72 h from 1 ml, 15 % acrylamide
implants containing 12.5 mg BSA polymerized in a 1 ml polypropylene syringe.
Implant Time (H)
0 1 2 3 4 8 16 24 48 72
# 1 0.78 1.48 2.00 2.38 2.68 3.10 4.32 4.95 6.64 7.81
# 2 0.58 0.82 0.82 0.96 0.96 1.24 1.96 2.63 4.41 5.78
Average 0.68 1.15 1.41 1.67 1.82 2.17 3.14 3.79 5.52 6.80
SEM 0.10 0.33 0.59 0.71 0.86 0.93 1.18 1.16 1.12 1.01
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Experiment 6- pFSH release from a 0.5-ml, 15 % PA implant with 2.5 mg pFSH in 0.6 ml
Eppendorf tube scaffolding
Table A.15 Cumulative protein release (mg) over 24 h from 0.33 ml, 15 %
acrylamide implants containing 2.6 mg pFSH, polymerized in a 1 ml syringe, then
placed in an outer-scaffolding of 0.6-ml Eppendorf tube.
Implant Time (H)
0 1 2 3 4 8 16 24
# 1 0.15 0.67 0.87 0.91 1.00 1.17 1.61 1.80
# 2 0.04 0.79 1.34 1.42 1.51 1.74 2.21 2.32
# 3 0.05 0.92 1.17 1.50 1.66 1.97 2.44 2.62
# 4 0.16 0.43 0.62 0.71 0.82 1.06 1.60 1.76
# 5 0.02 0.45 0.67 0.84 1.00 1.24 1.76 2.02
Average 0.08 0.65 0.93 1.08 1.20 1.44 1.92 2.10
SEM 0.03 0.09 0.14 0.16 0.16 0.18 0.17 0.16
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In-vivo Trial with Geldings
A.16 eFSH concentrations (ng/ml) of control geldings over 4 days.
Time
(H) Horse # MEAN SEM
6 9 11 16
-24 20.0 21.4 8.4 12.7 15.63 3.07
-12 22.0 20.4 10.7 18.0 17.78 2.50
0 20.1 13.8 8.9 13.9 14.18 2.29
6 19.1 19.8 12.2 19.5 17.65 1.82
12 20.8 20.0 10.6 14.0 16.35 2.44
18 20.9 20.8 11.6 18.4 17.93 2.19
24 24.4 21.1 15.6 19.1 20.05 1.84
30 25.7 16.1 6.6 15.8 16.05 3.90
36 27.2 19.1 14.0 17.8 19.53 2.78
42 27.3 23.6 11.7 15.5 19.53 3.59
48 23.8 17.8 12.0 14.6 17.05 2.54
60 20.3 19.4 10.3 15.2 16.30 2.29
72 20.4 24.1 15.4 15.7 18.90 2.08
84 21.2 14.7 10.3 17.0 15.80 2.27
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A.17 eFSH concentrations (ng/ml) for eFSH injected geldings over 4 days.
Time
(H) Horse # MEAN SEM
1 2 3 15
-24 6.6 9.6 13.0 4.7 8.48 1.81
-12 7.7 10.2 16.2 4.3 9.60 2.51
0 6.0 10.5 12.2 3.8 8.13 1.95
6 8.6 14.5 18.5 8.3 12.48 2.46
12 9.3 9.1 17.8 8.3 11.13 2.24
18 12.2 14.6 24.9 10.5 15.55 3.23
24 16.4 17.9 22.0 8.4 16.18 2.85
30 11.0 14.3 19.7 6.7 12.93 2.74
36 14.2 13.2 18.1 8.5 13.50 1.97
42 12.8 13.8 16.0 7.2 12.45 1.87
48 10.9 14.4 12.8 5.8 10.98 1.87
60 12.3 13.1 18.6 5.6 12.40 2.66
72 10.6 13.4 15.9 6.0 11.48 2.12
84 8.8 11.3 16.2 5.0 10.33 2.35
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A.18 eFSH concentrations (ng/ml) for FSH implant geldings over 4 days.
Time
(H) Horse # MEAN SEM
5 8 10 12
-24 8.0 9.0 20.6 30.3 16.98 5.28
-12 9.4 6.4 14.1 15.3 11.30 2.07
0 10.4 5.9 14.4 . 10.23 2.13
6 10.3 7.2 16.2 26.9 15.15 4.34
12 9.6 7.3 15.4 34.9 16.80 6.27
18 10.0 8.2 18.5 32.2 17.23 5.47
24 10.0 9.2 21.3 29.7 17.55 4.90
30 12.4 6.4 18.4 36.1 18.33 6.41
36 11.6 11.5 21.9 40.0 21.25 6.71
42 11.0 9.6 20.3 39.6 20.13 6.91
48 10.7 9.8 15.8 29.6 16.48 4.57
60 10.0 7.4 16.2 28.5 15.53 4.70
72 12.5 9.9 17.3 32.8 18.13 5.13
84 10.3 9.3 19.0 35.8 18.60 6.13
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In-vivo Trial with Heifers
Table A.19 FSH concentrations (ng/ml) for heifer injected group over 8 days.
Time (H) Heifer #
1 2 4 9 10 12 Mean SEM
-60 1.01 0.78 0.62 0.95 1.19 1.23 0.96 0.10
-48 0.75 1.03 0.83 1.15 0.98 1.14 0.98 0.07
-36 0.97 0.82 1.01 1.31 1.64 1.08 1.14 0.12
-24 1.03 1.19 0.83 1.26 0.95 1.16 1.07 0.07
-12 1.23 1.45 0.93 1.26 1.25 1.15 1.21 0.07
0 1.50 1.22 1.31 1.26 1.08 0.96 1.22 0.08
12 1.44 1.42 1.11 1.22 1.24 0.96 1.23 0.07
24 1.08 0.77 1.03 0.85 0.93 1.05 0.95 0.05
36 0.86 0.73 1.05 0.77 0.99 0.85 0.88 0.05
48 0.91 0.81 0.98 0.88 0.76 0.89 0.87 0.03
60 0.99 0.89 0.99 1.43 1.00 0.81 1.02 0.09
72 0.75 0.56 0.90 0.99 0.87 0.71 0.80 0.06
84 0.98 0.50 0.78 1.01 0.97 0.86 0.85 0.08
96 1.30 0.80 0.90 1.20 0.92 3.93 1.02 0.09
108 0.93 0.65 0.74 1.02 0.44 0.89 0.78 0.09
120 0.55 0.67 0.50 1.00 0.78 0.77 0.71 0.07
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Table A.20 FSH concentrations (ng/ml) for heifer implant group over 8 days.
Time (H) Heifer #
3 5 6 8 11 Mean SEM
-60 1.12 1.10 0.87 0.86 0.81 0.95 0.07
-48 0.85 1.13 0.82 0.58 0.62 0.80 0.10
-36 1.34 1.51 0.56 1.22 0.98 1.12 0.16
-24 1.43 0.74 1.00 1.38 1.12 1.13 0.13
-12 1.00 1.24 0.88 1.67 0.87 1.13 0.15
0 1.19 1.12 0.88 1.06 1.04 1.06 0.05
12 1.08 1.06 0.71 0.90 0.94 0.94 0.07
24 0.82 2.47 0.79 1.86 0.92 1.10 0.23
36 1.11 1.01 0.62 1.00 1.06 0.96 0.09
48 0.96 0.70 0.54 0.93 1.03 0.83 0.09
60 0.77 1.04 0.76 1.09 0.87 0.91 0.07
72 0.66 0.97 0.49 0.81 1.19 0.82 0.12
84 0.76 0.86 0.72 1.14 1.09 0.91 0.09
96 0.00 0.93 0.82 0.86 0.89 0.70 0.18
108 0.92 0.78 0.93 1.77 1.14 1.11 0.18
120 0.75 0.95 0.62 0.59 1.01 0.78 0.08
Table A.21 Ovulation data for 11 heifers.
Heifer #
1 2 3 4 5 6 8 9 10 11 12
ovulations on right 5 6 1 5 0 2 1 4 1 1 9
ovulations on left 6 10 1 11 1 0 1 10 0 1 8
Total ovulations 11 16 2 16 1 2 2 >20 1 2 17
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APPENDIX B
Acrylation of PEGDA
Table B.1: Substances needed for Acrylation of PEG procedure.
MW Purity Density Moles Amount
PEG 3400 3400 0.0059 20gm
-OH 1700 0.0118
Acryloylchoride 90.51 97% 1.114 0.0471 3.73 ml
Triethylamine 101.19 >99.5% 0.726 0.0518 7.22 ml
Toluene 92.14 >99% 0.866 150 ml
Neutral Alumina
Na2CO3 105.99 0.2353 24.94 g
Hyflo
Procedure
Drying of PEG:
• Take 20 gm of PEG (Table B.1), along with a stir bar in a round bottomed flask
• Add 150 ml of Toluene
• Immerse the round bottom flask in an oil bath and heat it to above 99
• Assemble Dean stark trap with molecular sieves.
• Apply Ar or N2 atmosphere and reflux for 1 h to dry PEG
• Remove oil bath and cool to room temperature
Acrylation of PEG:
• Add 1.865 g of acryloylchloride (at room temp)
• Add 7.22 ml of triethylamine after 5 minutes
• Cover the flask with aluminum foil
• Maintain a positive pressure of N2
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• Add another 1.865 g of acryloylchloride
• Stir dark for 4 h at room temperature (a yellow solution is obtained)
Filtration of Triethylamine – HCL Complex:
• Make thinnest layer possible of Alumina over Buchner funnel
• Take measured amount of Na2CO3 in a filter flask
• Apply vacuum and filter off the triethylamine-HCL complex
• Stir the heterogeneous solution obtained for 2h (in the dark)
• Make thinnest layer possible of Hyflo over the buchner funnel
• Remove the salt by filtration
Removal of Toluene:
• Take the toluene-acrylated PEG mixture into a rotovap
• Put the collecting flask in an ice bath
• Heat the toluene-acrylated PEG mixture under vacuum until all toluene is
removed (thick paste of PEG remains)
• Store crude product in freezer overnight
Precipitation of PEG:
• Dissolve the product in dichloromethane (use as little as possible)
• Precipitate the solution in ice cold diethylether (add solution dropwise with
continual stirring)
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• If the ether solution turns yellow, allow the precipitate to sink to the bottom
then decant the ether, add fresh ether and resume precipitation
• Isolate the product by filtration (under atmosphere)
• Rinse the product with ether
• Dry the product in Vacuo
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APPENDIX C
BIO-RAD Protein Assay
Procedure was based on BIO-RAD protocol, modified and validated in Dr. T Scott’s lab,
Animal and Veterinary Sciences Department at Clemson University. In-vitro results were
assayed using a form of the Bradford Protein Assay to determine protein release from
implants.
Plate set up
BIO-RAD Protein Assay Reagent Concentrate (BIO-RAD Laboratories, Hercules
CA) was diluted one part dye, four parts tap water. The linear range for standard curve
was 0.5 mg/ml to 0.03125 mg/ml. A stock solution of 10 mg/ml was used to create
standards.
.1 ml from stock added to 0.9 ml water/PBS = 1 ml of 1 mg/ml (Solution 1)
.1 ml of Solution 1 added to 0.5 ml water/PBS = 1 ml of 0.5 mg/ml (Solution 2)
.1 ml of Solution 2 added to 0.5 ml water/PBS = 1 ml of 0.25 mg/ml (Solution 3)
.1 ml of Solution 3 added to 0.5 ml water/PBS = 1 ml of 0.125 mg/ml (Solution 4)
.1 ml of Solution 4 added to 0.5 ml water/PBS = 1 ml of 0.0625 mg/ml (Solution 5)
.1 ml of Solution 5 added to 0.5 ml water/PBS = 1 ml of 0.03125 mg/ml (Solution 6)
A blank of water (polyacrylamide experiments) or PBS (PEGDA experiments)
was used. 10 µl was added per well in triplicate of either the standard, blank, or
unknown. A multichannel pipette was used to add 200 µl of diluted dye to each well.
Plates were shaken for five minutes, then placed on KC4TM micro-plate reader (BIO-TEK
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Instruments Incorporated, Winook, VT) and read at 570 nm. Assays were run on a 96
well plate, non-sterile EIA/RIA flat bottom assay plate (Costar™, Corning Incorportated,
Corning NY).
1 2 3 4 5 6 7 8 9 10 11 12
A
B
C
D
E
F
G
H
Figure C.1 Typical Plate Diagram of a 96 well plate.
Blue= standards location, Red= blank location, Green= Unknown sample location
Calculating results of Bradford Assay
Results were given in Optical Density (OD) and must be further analyzed to give
protein concentrations. Each plate contained a standard curve. The triplicates were
averaged and then the blank amount subtracted from each average. The results were then
plotted and a trendline with linear equation and R2 value calculated. Unknown sample
triplicate were averaged and amount of blank subtracted (blanks differ for each plate).
Samples were then multiplied by the total amount of ml removed and total protein
released for that sample was calculated using the line of best fit of the standard curve.
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APPENDIX D
SSR Abstract
Assisted reproductive technologies, such as superovulation, are common methods
to increase reproductive capacity and genetic diversity; however, labor, costs, and
inconsistent results make superovulation inefficient and expensive. Conventional
superovulation procedures require multiple follicle stimulating hormone (FSH) injections
over several days, which contribute to increased labor and animal to animal variation. A
sustained FSH release implant would minimize animal stress, time, labor, and variation.
An efficient and predictable sustained FSH release implant should have an
adequate pore size (molecular weight FSH ~ 33 kDa) to allow for a consistent protein
release profile and should be non-toxic and non-biodegradable. Additional concerns
include efficiency of production, stability, cost, and dimension elasticity.
Experiments 1 and 2 evaluated the in vitro release profile from two base materials
used to produce sustained release implants: polyethylene glycol diacrates (PEGDA) and
polyacrylamide (PA). Implants were made as 1 ml matrices polymerized in a cylindrical
plastic mold (5.5 X 0.8 cm). In Experiment 1, PEGDA (n=3) was polymerized with
ultraviolet light (365 nm) over the course of 12 h. In Experiment 2, PA implants were
made with a total concentration of acrylamide at 15% (n=3) or 20% (n=3), and
polymerized during an exothermic reaction (1 h). Bovine serum albumin (BSA ~ 60
kDa), at a concentration of 12.5 mg protein per implant, was used as a test protein.
Numerical differences were observed in protein release profiles: at 24 h PEGDA implants
released 0.9 ± 0.2 mg (Mean BSA release ± standard error) of protein compared to the
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release of the 15% and 20% PA implants at 9.3 ± 1.2 mg and 3.7 ± 0.3 mg, respectively.
The PA protein release profiles were superior to PEGDA, releasing 74% (PA 15) and
31% (PA 20) of cumulative total protein over 72 h, compared to 7% released from
PEGDA. The PA base material produced more consistent release profiles, required fewer
materials and time, and was chosen for evaluation.
Experiment 3 involved in vitro evaluation of a 20% 2 ml PA implant with 25 mg
of equine FSH (eFSH) for 72 h. A 20% PA implant was chosen because it was more rigid
than the 15% PA implant. Cumulative release of protein (mg) from the PA implant was
11.7 ± 0.3 (46% total) at 24 h, 13.5 ± 0.3 (54%) at 48 h, and 14.6 ± 0.3 mg (60%) at 72 h.
An in vivo experiment was designed based upon these compelling data.
The 20% PA implants were inserted subcutaneously into twelve geldings
randomly allocated (n=4) into Control (blank implant), Injection (implant blank and two
12.5 mg eFSH injections 12 h apart), and Implant groups (implant with 25 mg eFSH). No
significant differences (p > 0.10) in FSH concentrations were found; however, high
animal to animal variation (average range of FSH; control = 9.3 ± 1.2, FSH injection=
13.1 ± 2.5, and FSH implant=19.3 ± 3.0, p = 0.01) possibly obscured treatment effects.
Further studies to characterize in vivo FSH release profiles will be conducted to
evaluate this novel FSH delivery system and its effect on follicular development. A
predictable FSH implant would be widely accepted by the superovulation industry for its
ability to increase efficiency and decrease stress, time, costs, labor, and animal to animal
variation.
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APPENDIX E
Polyacrylamide Formulations
Table E.1 Formulation of 40 % acrylamide stock solution used in polyacrylamide
implant development.
Material Volume
Acrylamide, > 99.9 % (BIO-RAD, Richmond CA) 9.5 g
Bis (BIO-RAD, Richmond CA) 0.5 g
Distilled Water 25 ml
Table E.2 Formulation for various percentages of total acrylamide, in
polyacrylamide implant formation.
Total %
PA
Stock solution-
40 % total
acrylamide
Distilled
water
TEMED (BIO-
RAD, Richmond
CA)
Catalyst stock -
10 % Ammonium
Persulfate
10 % 2.50 ml 7.45 ml 20 µl 50 µl
15 % 3.75 ml 6.20 ml 20 µl 50 µl
20 % 5.00 ml 4.95 ml 20 µl 50 µl
30 % 7.50 ml 2.45 ml 20 µl 50 µl
35 % 8.75 ml 1.20 ml 20 µl 50 µl
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APPENDIX F
Gelding Trial Pictures
Figure F.1 Dr. Riggs anesthetizing surgery site to prepare for implant insertion
Figure F.2 Gelding about to receive acrylamide implant
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Figure F.3 Acrylamide implant being placed subcutaneously in a gelding
Figure F.4 Implant inserted subcutaneously in a gelding
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Figure F.5 Preparation for implant removal
Figure F.6 Implant removal
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APPENDIX G
Heifer Trial Pictures
Figure G.1 Heifer ready for implant insertion
Figure G.2 A heifer receiving an FSH implant
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Figure G.3 Heifer with a subcutaneously placed FSH implant
Figure G.4 Obtaining blood through jugular veni-puncture
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